Newsroom.

(27 February 2025): Seventy-one experts from 54 organisations in Australia’s cell and gene ecosystem have been appointed to Cell and Gene Catalyst’s four expert working groups to action strategic projects that will benefit the industry.

(19 December 2024): The Catalyst continues to drive Australia’s cell and gene industry forward, fostering collaboration, amplifying the sector’s profile, and aligning advocacy efforts to achieve transformative outcomes.

(17 December 2024): AusBiotech invites member contributions for the April 2025 edition of the Australasian Biotechnology journal. 

 

(5 December 2024):  Monash University and The Florey Institute of Neuroscience and Mental Health researchers were announced as joint winners at AusBiotech 2024's Early-Stage Innovation Forum (ESIF), at our annual conference in Melbourne.  

(29 November 2024): Australia's leading advocate for life sciences, AusBiotech, today welcomes the appointment of Dr Dell Kingsford Smith to its Board of Directors.  

Dell joins the Board with more than 20 years of experience in clinical and commercial strategy across medical technology, pharmaceuticals, and vaccines. Her depth of expertise spans discovery to full commercialisation.  

(27 November 2024): On Tuesday, 19 November 2024, AusBiotech and MTPConnect jointly delivered Australia’s first National Biotech and Medtech Development and Commercialisation Summit in Canberra.

(25 November 2024): AusBiotech welcomes the newly appointed members of the independent Health Technology Assessment (HTA) Reform Implementation Advisory Group. 

(21 October 2024): AusBiotech seeks to elect one new Board Director, and nominations are now open. As a member of AusBiotech, you are eligible to nominate for election. If you would like to make a greater contribution to AusBiotech and the Australian life sciences sector, we invite you to apply. 

(14 October 2024): Advance Australia's thriving biotechnology and medtech sector; participate in the upcoming election as AusBiotech seeks to elect one new Board Director.

As Australia's leading national and global advocate for life sciences, AusBiotech is for its more than 3000 members, supporting their growth by building an Australian life sciences ecosystem that leads in development and commercialisation, creating high-quality, innovative life sciences companies.

(1 October 2024): Built by our members, to be the national voice of our sector we are proud to support our member's growth and leverage our national convening power to shape policy, foster knowledge sharing, and collaborate to advance life sciences in our country. Together, we work to help our members thrive.

(26 September 2024): AusBiotech’s biotech and medtech members are being invited to complete the organisation’s first annual AusBiotech Voice on Investment Survey.

(25 September 2024)  To Members and other persons entitled to notice of Annual General Meetings (AGM) of AusBiotech Ltd, the 2024 AGM of AusBiotech Ltd will be held at the Melbourne Conference and Exhibition Centre and in accordance with the AusBiotech Constitution on Thursday 31 October 2024 at 12.30pm -1.30pm AEDT to transact the following business:

(17 September 2024): As the father of Australian biotech, Leon Serry AM is remembered for his pioneering work as an investor and philanthropist founding Cicardian (now Opthea Ltd), establishing the foundation of Australia’s biotech investment industry.

(12 September 2024): The Federal Government has released the final report of the Health Technology Assessment (HTA) Review, marking the first comprehensive review of Australia’s HTA system in nearly 30 years.

(10 September 2024): AusBiotech is pleased to announce the appointment of Tamlyn O’Connor as its new Industry Growth Program Manager.

(5 September 2024): AusBiotech was pleased to be invited to participate in a HealthTech Roundtable and Business Luncheon with the Hong Kong Government’s Financial Secretary, Mr. Paul Chan, and members to discuss growth opportunities for Australian biotech in Hong Kong and Asia.

(2 September 2024): The workshop, in partnership by Australia’s Chief Scientist Dr Cathy Foley, aims to accelerate the take-up of and build the demand for quantum technologies in Australia’s health sciences sector.

(29 August 2024): AusBiotech is delighted to welcome two new senior leaders to its team with both roles focused on elevating and amplifying the voice of our members as we work to accelerate the growth of Australia’s biotech and medtech industry.

(29 August 2024): AusBiotech 2024 is Australia’s premier life science conference and the flagship event of Australia’s biggest week in biotech. This year will be the biggest programme to date, featuring over 60 engaging sessions and more than 200 speakers in Melbourne from 30 October-1 November.

(27 August 2024): R&D entities are encouraged to ask questions or log amendments ahead of the Australian Taxation Office (ATO) publishing its first annual ‘Report of data about Research and Development tax incentive entities’ in late September 2024.

(22 August 2024):  The Therapeutic Goods Administration (TGA) is seeking industry feedback on proposed changes to the Australian Essential Principles for Safety and Performance of medical devices (Essential Principles), to align with new European regulations.

(20 August 2024): Seasoned life sciences investor Dr Eric Shiozaki, DCVC Bio, to headline AusBioInvest 2024, Australia’s premier life sciences investment conference, in Melbourne this October.

(15 August 2024): AusBiotech is deeply saddened by the loss of Dr Iris Depaz, a long-standing advocate, and champion of Australia’s biotech sector who was known for her visionary leadership and commitment to advancing Australia’s biotech sector.
 

(13 August 2024): The five priorities and five imperatives will shape government’s science investment activities over the next decade to support its Future Made in Australia agenda.

(8 August 2024): The first round of Australia’s Economic Accelerator (AEA) grants is now open, with $180 million in funding available for researchers and industry partners to commercialise research related to the Federal Government’s priority areas.

(6 August 2024): AusBiotech is pleased to welcome Ms Rosanne Hyland as Deputy Chief Executive Officer after serving as Business Manager and Chief Operating Officer for five years.

(1 August 2024): As the national peak body for life sciences and Australian life sciences innovators, AusBiotech welcomed a large number of new members between  April and June this year including: AlphaRET, Canary Regulatory Affairs, CBE Pure Solutions, Charles River Laboratories Australia, Chimeric Therapeutics, Formrite Group, MahPharma, McCullough Robertson Lawyers, Nyrada Inc, PharmAust, TekCyte, UTS Faculty of Science, Viedoc Technologies AB, and Wellumio.

(30 July 2024): The Therapeutic Goods Administration (TGA) is seeking industry feedback on potential reforms to Part 5 of the Therapeutic Goods Regulation (the Regulations) 1990, with the aim of developing a modernised framework.

(25 July 2024): Emeritus Professor (John) Robin Warren AC is remembered for his pioneering work discovering the bacterium Helicobacter pylori (H. pylori) and its role in gastritis and peptic ulcer disease, after passing away at age 87.

(23 July 2024): AusBiotech is calling for expressions of interest from researchers and inventors interested in pitching their innovation at our upcoming Early Stage Innovation Forum (ESIF) to be held at the AusBiotech 2024 national conference in Melbourne.

(23 July 2024): Neuren Pharmaceuticals (ASX:NEU) has received a Rare Paediatric Disease Designation from the US FDA for NNZ-2591 in Phelan-McDermid syndrome.

(18 July 2024):  The Department of Health and Aged Care is undertaking the survey to understand the demographic features, work environment, challenges, and motivations of health and medical researchers across Australia.

(16 July 2024): ASX-listed AusBiotech member Dimerix (ASX:DXB) takes out the Blake Award for Excellence after a knock-out year including an FDA conditional approval and key commercial partnerships.

(11 July 2024):  Shared advisory committees to be established following the Australian Government’s consultation on improving the Department of Health and Aged Care’s Medical Research Future Fund (MRFF) and NHMRC’s Medical Research Endowment Account’s (MREA) alignment.

(9 July 2024): Dr James Campbell, CEO & Managing Director, Patrys Limited (ASX:PAB), has been appointed as Chair of AusBiotech following a unanimous vote of the Board.

(4 July 2024): ASX-listed life science companies report a new market capitalisation of $252 billion, with Singular Health (ASX:SHG) topping return rankings for Q1, while Biome Australia (ASX:BIO) and Arovella Therapeutic (ASX:ALA) lead in earnings for 2024.

(2 July 2024): AusBiotech is calling for member contributions for the October 2024 edition of the Australasian Biotechnology journal.

(27 June 2024): Expressions of interest open for AusBiotech's First 100 Days Policy Taskforce, with industry leaders being called on to help shape key policy positions ahead of the 2025 Federal Election. 

(25 June 2024): New South Wales, Queensland, South Australia, Victoria, and Western Australia 2024-25 State budgets reflect evolving economic environment while continuing investments in life sciences infrastructure and commercialisation.

(20 June 2024): AusBiotech 2024 and AusBioInvest 2024, Australia’s premier life science and life science investment conferences, have opened early bird registrations.

(18 June 2024): The Australian Government’s $36 million-dollar Critical Technologies Challenge Program (CTCP) will support local quantum technology businesses to develop innovative solutions addressing nationally-significant challenges.

(13 June 2024): World-renowned cancer researcher Professor Karen Canfell and dozens of Australian clinicians and researchers have been celebrated in the King’s Birthday 2024 Honours List.

(11 June 2024): AusBiotech is seeking feedback on the Therapeutic Goods Administration (TGA)’s updated draft Companion Diagnostics (CDx) Guidance document to form an industry-led response.

(6 June 2024):  AusBiotech and BIO co-hosted ‘Investing in Australia’ roundtable brought Australian BIO delegates together with global leaders to enablement opportunities for trade and investment in Australia.

(4 June 2024): AusBiotech’s CEO, Rebekah Cassidy, and COO Rosanne Hyland, are on the ground at BIO 2024 in San Diego – working to support this year’s BIO 2024 mission to showcase Australia’s outstanding life science innovations, innovators and capabilities.

(4 June 2024): WIPO Member States approve treaty addressing intellectual property (IP), genetic resources, and associated traditional knowledge during a historic Conference in Geneva, Switzerland, after decades of discussions.

(30 May 2024): The JiffyStent Inserter, a Class 1 medical device looking to revolutionise kidney stone management, has taken out the title of best early-stage project at AusMedtech 2024’s Early-Stage Innovation Forum (ESIF).

(28 May 2024): AusBiotech is bringing Australia’s premier medical technology event, AusMedtech, to Sydney, New South Wales, in 2025 – the first time the conference has ever been held in the state.

(23 May 2024): Australia’s premier medical technology event, AusMedtech, is underway in Adelaide with more than 400 registered attendees. 

(21 May 2024):  The AusMedtech 2024 Clinical Trials Sector Dinner celebrates Australia’s reputation as a go-to destination for conducting clinical trials, in recognition of International Clinical Trials Day on 20 May.

(9 May 2024): The Cell & Gene Catalyst (the Catalyst) profiled the opportunities present in the Australian cell and gene ecosystem this week during BioKorea 2024.

(7 May 2024): The Therapeutic Goods Administration (TGA) is seeking professionals and consumers with expertise in relevant medical or scientific fields or consumer health issues, to support the world-class regulator’s functions.

(2 May 2024): The biotechnology, medical technology and pharmaceutical industry has applauded the $18.8m funding announcement for the National One Stop Shop (NOSS) for clinical trials, with the Research and Development Taskforce (RDTF) welcoming the opportunity this presents to Australia and Australians.

Appropriate and sustainable Federal Government funding is key to ensuring the platform becomes a reality. The NOSS will help actively position Australia as a globally competitive R&D destination bringing the latest medical therapies to Australian patients and creating further jobs and growth in the sector.

(30 April 2024): The programme for Australia’s inaugural boutique medtech investment roundtable, AusMedtechInvest 2024, is packed and features speakers from leading investment firms ARCHIMED, Artesian, Brandon Capital, Main Sequence, OneVentures, and Tenmile, as well as investment pitch presentations from medtech executives.

(23 April 2024):  Australia’s industry body for biotechnology, AusBiotech, has announced ex-Sanofi leader Rebekah Cassidy as its incoming Chief Executive Officer.

(18 April 2024):  AusBiotech has outlined two key recommendations in its response to Investment NSW’s Innovation Blueprint consultation: invest in sector maturation, and foster a culture of entrepreneurship.

(16 April 2024): The Australian Government has launched its Medical Science Co-Investment Plan, identifying four key investment opportunity areas in the medical science priority area: medical devices, complex therapeutics, digital health, and sustainability.

(11 April 2024) : AusBiotech and MTPConnect partner to support this year’s BIO 2024 mission to showcase Australia’s outstanding life science innovations, innovators, and unique capabilities.

(9 April 2024) : Australia’s Cell & Gene Catalyst (the Catalyst) invites the sector to join its first webinar outlining the opportunity it provides for Australia, and opportunity for engagement.

(4 April 2024):  Sponsors with medical device technologies on the Prescribed List (PL, formerly the Prostheses List) have four weeks to review their proposed benefits to inform the third and final reduction of PL benefits.

(2 April 2024): Inspired by its theme ‘United through Innovation’, AusBiotech is welcoming submission for topics and speakers to inform Australia’s largest life science conference, AusBiotech 2024, held in Melbourne from October 30-1 November.

(28 March 2024): The programme has launched for Australia’s largest medical technology conference, AusMedtech 2024, which will bring together more than 450 medtech thought leaders for the annual event.

(26 March 2024): Australia’s life science ecosystem is invited to join AusBiotech in supporting Australian Ethical’s statement supporting non-animal research models as and call on the government to implement a national strategy.

(21 March 2024): Australia’s Cell & Gene Catalyst (the Catalyst) has called for streamlined and equitable access for cell and gene (C&G) therapies in Australia in its response to the Department of Health and Aged Care’s Health Technology Assessment (HTA) Policy and Methods Review - Consultation 2.

(19 March 2024): Queensland-based biomedical companies, universities and research institutes are invited to apply for the Queensland Biomedical Business Attraction Program’s (QBBAP) latest funding round.

(14 March 2024): AusBiotech’s Board of Directors welcomes Dell Kingsford Smith, VP, Medical Affairs, Market Access & Government Affairs, Cochlear, as Board Observer.

(12 March  2024): A life science-specific Australian Stock Exchange (ASX) data feed has been launched on AusBiotech’s website with the aim of increasing the profile of and investment into Australia’s biotechnology companies.

(7 March  2024): More than 650 life science professionals will gather tomorrow for AusBiotech’s annual NSW Women in Life Sciences Luncheon to examine the pathways to greater economic inclusion for women in biotechnology.

(5 March  2024): AusBiotech Members are invited to register for a virtual discussion forum to support its industry-led response to Investment NSW’s Innovation Blueprint. 

(29 February 2024):  AusBiotech has responded to the Therapeutic Goods Administration’s annual fees and charges consultation, urging the Government to reconsider how the TGA’s digital transformation is funded.

(27 February 2024): Recommendations to drive diversity and inclusion of people underrepresented in STEM education and jobs are outlined in the Federal Government’s Pathway to Diversity in STEM Review report.

(22 February 2024): AusBiotech welcomes the Therapeutic Goods Administration (TGA) decision to exempt laboratories’ requirement to register Class 4 in-house IVDs on the Australian Register of Therapeutic Goods (ARTG) for stool donor screening test kits. 

(20 February 2024): AusMedtechInvest 2024, Australia’s inaugural boutique medtech investment roundtable forum, will provide a brand new forum to connect capital with innovation, with medical technology (devices and diagnostic) businesses and investors invited to register.

(15 February 2024): CSIRO’s ‘Innovate to Grow’ virtual programme is now seeking applications from Australian medtech and digital health companies interested in accessing research and development (R&D) support.

(13 February 2024): With the announcement of the NSW Women in Life Sciences Luncheon 2024 speakers, industry is encouraged to register for the must-attend event taking place on International Women’s Day, as seats at the table are limited.  

(8 February 2024): Medtech entrepreneurs are being invited to the Early-Stage Innovation Forum (ESIF), a unique platform for developers to pitch their innovation at the 2024 AusMedtech national conference in Adelaide.

(6 February 2024): A 2024-25 Pre-Budget submission urging for sustainable funding for the Government's National One Stop Shop for clinical trials has been submitted by the Research and Development Taskforce, a multi-sector collaboration between AusBiotech, Medicines Australia and the MTAA.  

(1 February 2024): Thirty-two experts from across the cell and gene ecosystem have been appointed to Australia’s Cell & Gene Catalyst’s (the Catalyst) three working groups.

(30 January 2024): The contributions of dozens of Australian clinicians and researchers have been celebrated in the Australia Day 2024 Honours List, with two University of Sydney Professors named Australian of the Year.

(25 January 2024): AusBiotech members are invited to share their views at a virtual roundtable on capital attraction incentives, to help finalise AusBiotech’s Investment in industry-driven medical research policy paper.

(23 December 2024): It’s that time of year where we return at our most refreshed and teeming with ideas and resolutions to make this year the most successful yet. AusBiotech’s commitment to the sector remains stronger than ever, with the new year providing a timely opportunity to revise and refresh strategic priorities for the year ahead.

(19 December 2023): The past 12 months have been significant in progressing Australia’s biotechnology industry. With the collective efforts and foresight of industry, we have many successes to be proud of, initiatives to celebrate, stories to share, and new ground that’s been broken.

(15 December 2023): Ms Rosanne Hyland appointed as Acting CEO of AusBiotech

(14 December 2023): AusBiotech is calling for member contributions for the April 2024 edition of the Australasian Biotechnology journal.

(12 December 2023): As part of Australia’s biggest week in biotech, clinical trial luminaries connected over dinner as part of a new initiative to celebrate the strength and success of Australia’s network.

(12 December 2023): AusBiotech has announced Professor Skerritt's appointment to its board. It has also announced that Dr Liz Dallimore, the CEO and managing director of Argenica Therapeutics, will join its board.

(7 December 2023): Three Expert Working Groups are being established to help support the Cell and Gene Catalyst’s (The Catalyst’s) strategic objectives in key priority areas.

(5 December 2023):  A NSW-focused strategy has been launched by AusBioNSW, to be led together with the newly appointed AusBioNSW Leadership Committee Chair Lis Boyce, Piper Alderman.

(30 November 2023): Publication of the NRF’s investment mandate is a welcome step forward in establishing the $15 billion programme for Australia’s innovation industries. 

(28 November 2023): AusBiotech urges policy makers to take a national approach to capability mapping and introduce targeted initiatives, in response to Federal Government’s discussion paper, Understanding our RNA potential.

(23 November 2023): AMR is an increasing global health priority, estimated to be directly responsible for 1.27 million deaths worldwide in 2019.

(23 November 2023): The Australian Cell & Gene Catalyst has issued its response to the federal government's health workforce scope of practice review.

(21 November 2023): QIMR Berghofer and Murdoch University researchers announced as joint winners at AusBiotech 2023’s Early-Stage Innovation Forum (ESIF) held in Brisbane on 3 November.  

(16 November 2023): Parliament House Canberra hosted biotech leaders for a day of discussions and presentations with the government, as AusBiotech’s annual Policy Forum headed to the Hill.

(14 November 2023): The AusBiotech-commissioned ‘Economic impact of the Research & Development Tax Incentive (RDTI) for the biotech industry’ report underlines the critical role of Government in developing and retaining fit-for-purpose policy beyond election cycles.

(9 November 2023): AusBiotech’s Board of Directors welcomes Dr Iris Depaz, Sanofi Australia & New Zealand, to the Board, while farewelling three Directors and Board Observer at AusBiotech 2023 in Brisbane.

(1 November 2023): Australia’s premier life science conference attracts more than 1,200 delegates representing life science professionals from 22 countries to ‘advance biotech’.

(31 October 2023): Australia’s premier life science investment conference attracts more than 280 delegates representing investors and life science professionals from 13 countries. 

(26 October 2023): ASX-listed Impedimed Limited Pharmaceuticals (ASX:IDP), Avita Medical (ASX:AVH), and Neuren Pharmaceutical (ASX:NEU) lead in share price increase for 2023 while Lumos Diagnostics (ASX: LDX) tops Q3 rankings.

(24 October 2023): Australia’s premier life science investment conference unveils esteemed speaker line up and 26 Australian biotech companies pitching for partnerships. 

(19 October 2023): Jennifer Nason, Global Chairman of Investment Banking, J.P. Morgan, to share insights on global capital markets and what that means for Australian biotech at AusBioInvest on October 30 in Melbourne.

(17 October 2023): Professor Michelle Simmons, Professor Chris Greening, Professor Glenn King, and Associate Professor Lara Herrero have been recognised for their extraordinary contributions to science at the 2023 Prime Minister’s Science awards in Canberra.

(12 October 2023): Inaugural AusBiotech Life Sciences Legacy Award winner Mr Chuck (Charles) Feeney AC is remembered for his significant contributions to Australia’s medical research and life sciences sector, after passing away aged 92.

(12 October 2022): It has come to our attention that a company is seeking to sell a contact list that is titled with AusBiotech’s name - in an unapproved manner.

(10 October 2023): An introductory in-person training on the new Prescribed List (PL) products is occurring on 8 November for sponsors to gain critical insights for PL applications.

(5 October 2023): Australia’s Cell and Gene Catalyst (Catalyst), has a new leader at the helm with the appointment of accomplished scientist and executive Dr Marguerite Evans-Galea AM as Catalyst Director.

(4 October 2023): This amended Notice of AusBiotech’s AGM for the AGM scheduled for Thursday, 2 November 2023 replaces (in full) the original notice of AusBiotech’s AGM circulated on August 14, 2023. 

(3 October 2023): Prepare your company profile in the Australian Life Sciences Innovation Directory ahead of AusBiotech 2023 and AusBioInvest 2023.

(28 September 2023): Australia’s life science strengths and success stories highlighted in the latest edition of Australasian Biotechnology, AusBiotech’s official journal, in anticipation of the upcoming AusBiotech 2023 and AusBioInvest 2023 conferences.

(26 September 2023): Tessara Therapeutics, Harrison.ai, and Baymatob selected as finalists in 2023 InnovationAus Awards for Excellence’s HealthTech category.

(21 September 2023): AusBiotech CEO, Ms Lorraine Chiroiu, has announced she will hand over the leadership of AusBiotech, after more than five years at the helm and 15 years of successful and dedicated service to the organisation and the life sciences sector - effective from 15 December 2023.

(19 September 2023): Momentous announcement from GSK marks key inflection point in Professor Andrew Wilks’ 20-year journey.

(14 September 2023): The one-day agricultural biotechnology event held onsite alongside the AusBiotech 2023 national conference has launched its programme, featuring sessions on sustainable food production, First Nation partnerships, and capital raising in the agritech sector.

(12 September 2023): Member feedback is invited on a new draft policy whitepaper supporting access to great talent through the Employee Share Schemes (ESS), as AusBiotech works to ensure Australia’s future as an internationally-competitive environment for biotechnology.

(7 September 2023): Secure your early-bird registration to Australia’s premier life sciences event, AusBiotech 2023, before 18 September, save up to $350, and join industry in celebrating Australia’s biggest week in biotech.

(5 September 2023): A new report has been released on ‘Non-animal models: a strategy for maturing Australia’s medical product development capabilities’, with CSIRO highlighting how by acting now, Australia can secure a key role and deliver around $1.5B in growth in this emerging capability.

(31 August 2023): An evaluation of the MRFF’s Clinical Trials Activity initiative has found that MRFF-funded trials have enhanced research translation, by involving industry, consumers, and professional organisations in trials, increased research into unmet need particularly in rare cancers, and helped more Australians access clinical trials.

(29 August 2023): AusBiotech is calling for feedback on newly drafted TGA guidance on the requirements for Class 4 in-house IVDs used for screening Faecal Microbiota Transplant (FMT) donors, and on the proposal to cease the current exemption for these IVDs that are used for FMT donor screening from inclusion in the ARTG from 1 July 2025.

(22 August 2023): A US venture capitalist, with a track record of successful investing in Australian biotech, will headline Australia’s premier life sciences investment conference, AusBioInvest 2023, in October.

(22 August 2023): Help advance Australia’s biotechnology sector: nominations are open for the AusBiotech Board of Directors, as it seeks to elect one new director.

(17 August 2023): The AusBiotech 2023 national conference programme is today launched featuring over 50 engaging sessions and more than 100 speakers in Brisbane from 1-3 November, highlighting Australia’s role in advancing biotechnology on the world stage.

(15 August 2023): Distinguished Australian scientist Emeritus Professor Ian Frazer AC to deliver Millis Oration at AusBiotech 2023 national conference in Brisbane.

(14 August 2023): To Members and other persons entitled to notice of Annual General Meetings (AGM) of AusBiotech Ltd, the 2023 AGM of AusBiotech Ltd will be held at the Brisbane Convention & Exhibition Centre and in accordance with the AusBiotech Constitution on Thursday 2 November at 12.30pm - 1.20pm (AEST) to transact the following business:

(10 August 2023): AusBiotech’s landmark A Practical Guide to ESG for Australian Life Sciences Companies is launched to help SMEs attract investment and navigate environmental, social and governance (ESG) reporting. 

(8 August 2023): AusBiotech urges Federal Government to take biotechnology industry’s unique characteristics into account when designing $392.4 million Industry Growth Program.

(3 August 2023): Australia continues to attract significant investment from US investors, with the total figure of US investment into Australian life science companies totaling US1.43 billion and a strong growth trend over the five-year period, between 2018-2022.

(1 August 2023): AusBiotech states process must not overtake purpose behind funds, in response to consultation paper Improving alignment and coordination between the Medical Research Future Fund and NHMRC’s Medical Research Endowment Account (MREA).

(27 July 2023): ASX-listed AusBiotech member Neuren Pharmaceuticals (ASX:NEU) swoops up Blake Award for Excellence after a knock-out year including an FDA approval and key commercial partnerships.

(25 July 2023): The Federal Government’s Women for STEM Ambassador releases systemic review of gender equity initiatives in Australia with recommendations on effectively implementing programmes in STEM workforce.

(20 July 2023): A new National Cell and Gene Manufacturing Blueprint launched today, outlining how, with a united and coordinated plan, Australia can realise its potential to become a cell and gene (C&G) manufacturing hub for within the Asia-Pacific (APAC) region. 

(18 July 2023): AusBiotech welcomes the Therapeutic Goods Administration’s (TGA) confirmation that the Clinical Trials Notification (CTN) and Clinical Trials Approval (CTA) pathways remain unchanged, following consultation on ‘proposed changes for clinical trials of medical devices’.

(13 July 2023): The Early-Stage Innovation Forum (ESIF) is calling for expressions of interest from developers interested in pitching their innovation at the 2023 AusBiotech national conference in Brisbane.

(11 July 2023): Members of AusBiotech are encouraged to share news and announcements for prioritised inclusion in twice-weekly industry news updates.

(6 July 2023): Accomplished scientist and partnership executive Dr Robyn Lindner has been appointed as General Manager, AusBioNSW, bringing with her more than 25 years’ experience in life sciences. 

(4 July 2023): Takeda Pharmaceutical is inviting Australian researchers and companies to submit early-stage research proposals for neuroscience, oncology, gastroenterology and platform technology projects.

(29 June 2023): AusBiotech is calling for member feedback on the design of the Federal Government’s new $392.4 million Industry Growth Program that will provide expert advice and funding to innovative Australian SMEs.

(27 June 2023):  AusBiotech is calling for member contributions for the September 2023 edition of the Australasian Biotechnology journal. 

(22 June 2023): ASX-listed life science companies report a new market capitalisation of $255 billion, with Arovella Therapeutic (ASX: ALA) and Avita Medical (ASX: AVH) topping return rankings for Q1 while Neuren Pharmaceuticals (ASX:NEU) leads in earnings for 2023.

(20 June 2023): Life sciences is a growing priority on state government agendas, with South Australia, Queensland, Victoria, and Western Australia 2023-24 State budgets earmarking a combined $179.1 million to provide industry, SMEs and manufacturing support.

(15 June 2023): Consultation has opened on improving the alignment between Commonwealth funds, the Medical Research Future Fund (MRFF) and Medical Research Endowment Account (MREA), and as the national voice of industry, AusBiotech is seeking its members’ views.

(13 June 2023): Dr Anna Lavelle has been awarded a Member of the Order in the King’s Birthday Honours for her significant service to science and innovation.

(8 June 2023): The long-awaited National One Stop Shop for clinical trials consultation report has been released by the Australian Commission on Safety and Quality in Health Care, revealing five key recommendations for implementing a single, national clinical trials platform.

(6 June 2023): Australia’s largest-ever delegation to the world’s largest life sciences convention, led by AusBiotech, highlights industry’s commitment to fostering global collaborations and partnerships.

(1 June 2023): A Guide to support Australian life sciences companies navigate their ‘environmental, social and governance’ (ESG) reporting has been developed, and AusBiotech is seeking industry feedback to finalise the resource for industry implementation.

(30 May 2023): A project from QIMR Berghofer was announced the winner of the Best Translational Research at AusMedtech 2023’s Early-Stage Innovation Forum (ESIF) held in Adelaide last week.

(25 May 2023): A new programme aimed at supporting small to medium (SMEs) health and medical companies developing new products and services is open for applications.

(23 May 2023): Australia’s premier medical technology event, AusMedtech, starts tomorrow with more than 400 registered attendees.

(18 May 2023): In recognition of International Clinical Trials Day on 20 May, AusBiotech celebrates Australia’s global reputation as a go-to destination for conducting clinical trials.

(16 May 2023): A new white paper reveals how system change is required to ensure Australians can access the 2,000 cell and gene therapies (CGTs) currently in development globally, and recommendations on how best to prepare the national health landscape to seize the opportunity.

(11 May 2023): Following the 2023 Federal Budget announcements, AusBiotech has welcomed support for SMEs and start-ups through a new ’Industry Growth Programme’ and potential procurement measures, and lamented the noticeable absence of Australia’s One Stop Shop for clinical trials, a sustainable funding model for the TGA, and the end of the EMDG progamme. 

(9 May 2023): AusBiotech is proud to support Austrade’s BioKorea 2023 delegation to strengthen ties with international markets, and highlight investment opportunities in Australia and our national life science capabilities. 

(4 May 2023): Registrations for AusBioInvest 2023, the largest investment and partnering conference in the Australian life sciences sector, have opened, and investors, company executives and delegates are invited to register today.

(2 May 2023): Get ready to find potential partners and ensure you can be found through the Australian Life Sciences Innovation Directory.

(27 April 2023): AusBiotech has welcomed Minister Husic’s attendance and engagement at an Industry Forum, held in Sydney last week with key CEOs, to discuss the Biotechnology Blueprint, a decadal plan for the industry’s future.   

(20 April 2023): Based on flimsy rationale and opposition from medical devices developers, AusBiotech is urging the Federal Government not to push ahead with the proposed regulatory changes that will see a more onerous approval process for numerous implantable medical device clinical trials - which will cause delays and red tape, but may not enhance patient safety.

(18 April 2023): The National Industry PhD Program is seeking suitably qualified individuals with an interest in being industry-based assessors. 

(13 April 2023): As we approach the final runway to the medtech conference of the year, AusMedtech 2023, those in medical devices and diagnostics are invited to register and get involved, to pitch, partner, network and learn what’s on the horizon for the medtech industry. 

(11 April 2023): The Australian Academy of Technological Sciences & Engineering (ATSE) is undertaking a survey in partnership with the Department of Education to research translation and commercialisation in Australia. 

(6 April 2023): Australia’s Chief Scientist, Dr Cathy Foley, is leading a national conversation on Science and Research Priorities, which is in its final stages.  

(4 April 2023): AusMedtech 2023 will feature an early-stage innovation pitching event featuring presentations from Australia's emerging early-stage medical technologies. 

(30 March 2023): Ahead of assessments commencing under the National Safety and Quality Health Service Standards, you are invited to join online workshops on the National Clinical Trials Governance Framework. 

(30 March 2023): “The Government’s $15 billion National Reconstruction Fund is one of the largest peacetime investments in Australian manufacturing capability,” said industry and science minister, Ed Husic.

(28 March 2023):  The programme for this year’s national medical technology conference, AusMedtech 2023, has launched with a focus on the future of healthcare. 

(23 March 2023): AusBiotech has launched a directory of accelerators and incubators relevant to Australian life sciences companies, providing a valuable new resource for biotech, medtech and digital health companies in the early stages of their development. 

(21 March 2023): Industry and research organisations representing Australian health innovators have joined together to reiterate the sector’s considerable support for the National Reconstruction Fund (NRF) - calling on all parties to support the NRF Corporation Bill 2022 through the Senate.   

(16 March 2023): Call for speakers for biggest week in biotech.  With the theme ‘Advancing Biotech - It’s in our DNA’, AusBiotech is welcoming submissions for topics and speakers to inform Australia's largest life sciences conference programme.

(14 March 2023): The passing of the $15bn National Reconstruction Fund (NRF) Corporation Bill through the House of Representatives is a positive step forward for all Australians, as it takes the fund closer to reality.

(9 March 2023): Australian biotech stocks were only down slightly in 2022 compared to 2021 and remain higher than pre-Covid levels, despite the first half of the year being the worst biotech half year on record, according to Bioshares’ latest report.

(7 March 2023): In celebration of International Women’s Day (IWD) this week, more than 520 life science leaders will gather this Friday for AusBiotech’s annual NSW Women in Life Sciences Luncheon, to encourage, support and further develop opportunities to Embrace Equity in the life sciences sector.

(2 March 2023): AusBiotech and Medicines Australia have announced the next phase of their joint venture, the Cell and Gene Catalyst (the Catalyst), with the appointment of a new General Manager to drive the initiative, key priority areas identified and expert working groups currently being established.

(28 February 2023): AusBiotech urges a Federal Government review of the TGA funding model, as it prepares its response to the annual TGA fees and charges proposal released last week.

(23 February 2023):  The highly-popular Australian Pavilion will be back at BIO in Boston this year, showcasing the Australian biotech industry at the world’s largest and most influential global life sciences conference.

(21 February 2023): AusBiotech has commissioned research into what is required in order for Australia to manufacture more cell and gene products.

(16 February 2023): AusBiotech welcomes WA’s recently-launched Health and Medical Research Strategy 2023 – 2033, which recognises the importance that biotech delivers socially and economically to Australia.

(14 February 2023): A group of dedicated AusBiotech leaders have banded together to develop an Australian biotech first, a sector-specific ‘environmental, social and governance’ (ESG) tool, to help companies attract investment and navigate ESG reporting.

(9 February 2023): The Australian Commission on Safety and Quality in Healthcare has launched a public consultation on its revised clinical quality registries framework, and AusBiotech members impacted by the guidance are invited to get in touch.

(7 February 2023): On behalf of its members representing the Australian life sciences industry, AusBiotech has welcomed the opportunity to respond to the $15 billion National Reconstruction Fund (NRF) consultation and put forward a number of recommendations in its submission as the Fund seeks to “add value and develop capability … to create high quality, sustainable industries and jobs”.

(2 February 2023): Gender equality expert and thought leader Dr Kathryn J Evans has been announced as the keynote speaker for the Women in Life Sciences Luncheon in Sydney on 10 March 2023, co-hosted by AusBiotech and Medicines Australia.

(1 February 2023): AusBiotech is pleased to announce the latest appointment to its Board of Directors, Erica Kneipp, who brings with her extensive government expertise and policy experience, relevant to the Australian health sector. 

(31 January 2023): AusBiotech has united with industry groups to urge the Government to retain and empower Australia’s world-leading regulator by addressing the outdated funding model it operates under, and to fund its worthy public health initiatives through the upcoming Federal Budget. 

(24 January 2023): AusBiotech welcomes the recent announcement of a $40 million Biosciences Fund (BioSF) for NSW startups, researchers, and entrepreneurs to help them realise their full potential and assist them to bring their innovations to market.

(19 January 2023): AusBiotech is inviting member feedback on its draft submission to the Australian Government’s $15 billion National Reconstruction Fund (NRF) consultation.

(17 January 2023): It’s that time of year again when we return from the festive break brimming with energy, new ideas and resolutions. At AusBiotech, our commitment to the sector is even greater, with a firm resolution to amplify our efforts even further in supporting and advocating for the growth of the life sciences industry.

(20 December 2022): It has been a year to remember, when the biotech sector ‘came alive’ and reunited in person once more, as witnessed in the record attendance at our national conference and other industry events. Despite the many challenges, the life sciences sector has continued to push boundaries with innovative approaches and technologies at the forefront.

(15 December 2022): ARCS has recently launched the ARCS Signature Program, aimed at equipping senior industry leaders with local industry knowledge.

(13 December 2022): Consultations on the National Reconstruction Fund (NRF) have now opened, and AusBiotech is inviting members to join its roundtable discussion to have their say and shape industry’s submission so it best meets the sector’s needs.

(08 December 2022): AusBiotech is encouraging the biotech sector to nominate talented industry colleagues for the 2023 Prime Minister’s Prizes for Science, Australia’s most prestigious awards for outstanding achievements in science.

(06 December 2022): Medtech will take centre stage as the key theme for the April 2023 edition of AusBiotech’s Australasian Biotechnology journal, and industry experts interested in sharing their insights and innovations are invited to get in touch.

(01 December 2022): The introduction of the $15bn National Reconstruction Fund (NRF) has been welcomed by AusBiotech as a positive step forward, and the investment of the ‘medical science’ funds moving closer to reality.

(29 November 2022): AusBiotech welcomes a new report on artificial intelligence (AI) from CSIRO, designed to help those in the science sectors get a greater understanding of AI, how it’s changed and what the future holds for Australia in particular.

(24 November 2022): Antimicrobial resistance is a ‘silent pandemic’, estimated to kill 10 million people every year from 2050, according to a new video from the International Council of Biotechnology Associations (ICBA), which includes AusBiotech.  

(22 November 2022): Parliament House Canberra will today host biotech leaders for a day of discussions and presentations with the government.  The delegation of 27 CEOs will exchange on key topics in the Biotechnology Blueprint.  

(17 November 2022): Join us for our Australia-wide end-of-year functions to network with colleagues and friends and reflect on the year we’ve had. 

(15 November 2022): AusBiotech has welcomed the inclusion of commercialisation as a key priority in the recently launched Australian Medical Research and Innovation Priorities 2022-2024.

(10 November 2022): Projects from QIMR Berghofer Medical Research Institute and WEHI - The Walter and Eliza Hall Institute were this year’s joint winners of the AusBiotech 2022 Early-Stage Investment Forum (ESIF) after winning the pitching event judged by an independent expert investment panel. 

(8 November 2022): Registrations are now open to use AusBiotech's Australia Hub, which will be available to Australians heading to San Francisco during the annual JP Morgan Week in January 2023.  

(3 November 2022): In an era of innovation commercialisation, the latest election to AusBiotech’s Board of Directors, Dr Marthe D’Ombrain (Head of Global Research Innovation, CSL Limited), was announced at today’s Annual General Meeting and brings appropriate skills and experience to support growth of the industry.

(27 October 2022):  The Federal Budget, the first for the new Government, has delivered on the Government’s election promises, confirming a range of commitments with a notable cut to the Entrepreneurs’ programme.

(26 October 2022): Record numbers of life science delegates attend AusBiotech 2022; strong line-up at AusBioInvest 2022 held in the same week. 

(20 October 2022):  AusBiotech is inviting members to register for its upcoming 2022 Annual General Meeting (AGM), which will recognise and celebrate the achievements of the AusBiotech membership this year.  

(18 October 2022):  AusBiotech’s 2022 conference will feature a one-day AgBiotech Summit on Thursday 27 October 2022 in Perth, including a session on sustainable proteins in a nod to World Food Day. The Summit will profile Australia’s innovative agricultural biotechnology and promote the sector that's contributing to Australia’s food development process, from farm to plate.

(13 October 2022):  AusBiotech welcomes The Queensland Government’s $24 million Enterprise Acceleration Fund, which will aim to invest in innovative, early-stage Queensland companies, supporting increased access to investment capital and jobs growth.

(11 October 2022):  AusBiotech is seeking contribution from affected members as it considers its response to the Therapeutic Goods Administration’s (TGA) consultation on the International Medical Device Regulators Forum (IMDRF)’s ‘Boundary and combination products - medicines, medical devices, and biologicals’.

(6 October 2022): Industry has united through the Research and Development Taskforce (RDTF) to respond to the Therapeutic Goods Administration’s (TGA) consultation on proposed changes for clinical trials of medical devices and make a joint submission on maintaining regulation commensurate with risk.

(4 October 2022): AusBiotech is backing global advocacy efforts as the World Trade Organization considers expanding its Trade-Related Aspects of Intellectual Property Rights Agreement to therapeutics and vaccines. 

(29 September 2022): With AusBioInvest 2022 in four weeks on in Perth, WA on 27 October, Australian investment in biotechnology will be spotlighted and the recently released Health and Biotech Investor Guide from Stockhead and The Australian, profiles ten companies presenting at Australia’s largest life sciences investment conference.

(27 September 2022): Australia’s captivating biotech sector has ‘come alive’ in the latest edition of Australasian Biotechnology, AusBiotech’s official journal, in anticipation of the upcoming AusBiotech 2022 and AusBioInvest 2022 conferences.

(20 September 2022): Nominations are open for the 2023 Johnson & Johnson Scholars Award programme that aims to develop female leaders and feed the talent pipeline.

(15 September 2022): The programme for Australia’s largest life sciences investment conference, AusBioInvest 2022, has launched; engaging capital with health innovation it features global and local keynotes and panelists sharing insights to support informed investment decisions in a complex scientific field, and up to 30 public and private Australian biotechnology company presentations.

(13 September 2022):  The Asia Pacific region has taken in the lead in cell and gene clinical trials, accounting for the largest share of new trials during the first half of 2022, reveals the Alliance of Regenerative Medicine’s latest report mapping the sector’s progress. 

(8 September 2022):  AusBiotech is delighted to announce Elizabeth Koff AM, Managing Director, Telstra Health will be delivering a keynote in-person at the industry’s national conference, AusBiotech 2022. The presentation titled global outlook on digital health will offer insights on how digital health is shaping Australian health systems.

(6 September 2022):  AusBiotech welcomes the release of the Department of Education’s voluntary Higher Education Research Commercialisation (HERC) Intellectual Property (IP) Framework to facilitate partnerships between universities and industry partners.

(1 September 2022):  The AusBiotech 2022 programme has launched and profiles five keynotes and 40 engaging panel sessions highlighting the pressing and emerging topics facing the Australian and global biotech sector.

(30 August 2022):  Nominations are open for the AusBiotech Board of Directors as it seeks to elect one new director.

(25 August 2022):  Regulatory changes have been proposed by the Therapeutic Goods Administration (TGA) for clinical trials of medical devices, and AusBiotech is calling for feedback from affected members as it considers the impact on industry.

(23 August 2022):  The Therapeutic Goods Administration (TGA) has recently commenced the recruitment process to welcome industry to apply for positions on its statutory advisory committees that will become vacant at the end of 2022. 

(18 August 2022):  Contributing to the Federal Government’s Jobs and Skills Summit’s Employment White Paper, AusBiotech is seeking feedback from members on the key enablers and opportunities that will help us meet our industry’s future skill and workforce needs.

(16 August 2022):  AusBiotech is seeking expressions of interest from expert members to assist with developing a new edition of The Code of Best Practice for Reporting by Life Sciences Companies (the Code) – a resource for Australian life sciences companies that encourages the adoption of high, consistent standards of communication and market disclosure, which in turn promotes investor confidence.

(15 August 2022): To Members and other persons entitled to notice of Annual General Meetings (AGM) of AusBiotech Ltd, the 2022 AGM of AusBiotech Ltd will be held on a virtual platform and in accordance with the AusBiotech Constitution on Thursday 3 November at 1.00pm - 2.00pm (AEDT) to transact the following business...

(11 August 2022):  AusBiotech is seeking expressions of interest from senior members who are passionate about environmental, social and governance (ESG) reporting to join a working group, as part of AusBiotech’s expanded offering of investment attraction initiatives.

(9 August 2022): It has come to our attention that a company is seeking to sell a contact list that is titled with AusBiotech’s name - in an unapproved manner.

(9 August 2022):  AusBiotech’s innovative Australian Life Science Innovation Directory, is an engaging platform where members can check and update their details to connect with other members in Australia’s thriving life sciences sector. 

(4 August 2022): AusBiotech is delighted to reveal a ‘sneak peek’ into the AusBiotech 2022 programme, which features global thought-leaders, and pressing and emerging topics to drive the Australian biotech sector forward.

(2 August 2022): Australia’s Cell and Gene Catalyst will move ahead, establishing its inaugural Steering Group and opening recruitment, formally signalling the important next step in advancing cell and gene accessibility in Australia.

(28 July 2022):  Nominations for the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards are now open and will recognise and celebrate life science leaders who are championing the sector and the Australian community.

(26 July 2022):  Data from IP Australia’s recently released Australian Intellectual Property Report 2022 highlighted ‘a record high’ 32,397 standard patent applications filed in Australia in 2021, which demonstrated an 11 per cent increase on 2020 filings.

(21 July 2022):  AusBiotech is seeking contribution from affected members as it considers its response to the Therapeutic Goods Administration’s (TGA) consultation on the International Medical Device Regulators Forum (IMDRF)’s Medical Device Cybersecurity Guide (MDCG) Working Group.

(19 July 2022):  AusBiotech welcomes the recent launch of The Australian Commission on Safety and Quality in Health Care (the Commission)’s National Clinical Trials Governance Framework.

(14 July 2022):  Therapeutics Goods Administration (TGA) has recently responded to stakeholder feedback on improving cell and gene regulation in Australia by releasing the ‘Cell, Gene and Tissue Regulatory Framework in Australia: Stakeholder Perspectives’ report.

(12 July 2022):  AusBiotech is pleased to announce an expanded investment attraction offering has commenced in line with a new investment attraction strategy. This strategy was developed in response to feedback from members and industry stakeholders during the development of the Biotechnology Blueprint; A Decadal Strategy for the Australian Biotechnology Industry.

(7 July 2022):  AusBiotech is pleased to partner with Australia’s national industrial research agency CSIRO to deliver three BioCheers networking events across August in Melbourne, Sydney and Brisbane.

(5 July 2022):  The WA State Government recently announced an innovative programme – the Co-Funding Partnerships Program (Co-FFP) – that aims to provide an avenue for researchers or organisations to co-fund and support health and medical research programmes to improve the health and wellbeing of Western Australians.

(30 June 2022):  AusBiotech has recently appointed Dr Darren Forrest, Director of Quality & Regulatory Affairs ANZ, Medtronic Australasia Pty Ltd as Chair of the national AusMedtech Regulatory Affairs Advisory Group.

(28 June 2022): AusBiotech welcomes the announcement of two new university-specific investment funds, totalling $115 million, created in collaboration with Tanarra Capital, the University of Melbourne and Victorian State Government-funded Breakthrough Victoria.

(23 June 2022): AusBiotech has welcomed the investment into the life sciences industry through this week’s New South Wales and Queensland Budgets, as well as the recognition of biotech’s ability to “underpin the jobs, businesses and industries of the future”.

(21 June 2022): A recent report published by US-based firm McKinsey & Company has cited that venture capital (VC) investment in the biotech industry has boomed over the past three years.

(16 June 2022): The Australian biotech community will ‘come alive’ at AusBiotech 2022, Australia’s premier life science conference, and with early-bird registrations now open now is the time to plan to recharge and reconnect.

(14 June 2022): The significant 40 per cent growth of Australia’s biotechnology industry in two years, revealed in AusBiotech’s new sector ‘snapshot’, is symbolic of the sector’s value to Australia and Australians.

(9 June 2022): This year’s annual Australian delegation to the largest biotech event in the world will return in-person next week, led by AusBiotech, and demonstrates a strong industry with participation bouncing back to pre-pandemic sizes.

(7 June 2022):  The Australian medtech community celebrated and championed eight early-stage start-ups at the recent AusMedtech 2022 Early-Stage Investment Forum.  

(2 June 2022): The Australian Commission on Safety and Quality in Health Care’s (The Commission) clinical trials ‘National One Stop Shop’ consultation has opened its second phase for health-related human research approvals. 

(31 May 2022): AusBiotech is calling for leadership articles to include in the September 2022 edition of the Australasian Biotechnology journal.

(26 May 2022): Demonstrating the buoyancy and growth of the sector, AusBiotech recorded its largest-ever face-to-face AusMedtech conference this week as the Australian medtech sector reunited and celebrated its achievements.

(24 May 2022): AusBiotech welcomes the 31st Federal Government of Australia, and extends its congratulations to incoming Ministers and elected members of Parliament.

(19 May 2022): AusBiotech is delighted to be presenting the inaugural Industry Partnership Award at the 2022 ACTA National Tribute and Awards Ceremony in Sydney, which coincides with the  celebration of International Clinical Trials (CT) Day on 20 May.

(17 May 2022): AusBiotech is calling for session proposals and speakers for Australia’s largest life sciences event of the year - AusBiotech 2022, to be held 26 - 28 October in Perth.

(12 May 2022): For the first time in 20 years, Australia’s biotechnology sector has united to launch the Biotechnology Blueprint: A Decadal Strategy for the Australian Biotechnology Industry - a shared industry vision and ‘blueprint’ navigating the biotech ecosystem as it aspires to build solid companies, create more jobs, commercialise more biotechnologies, build sovereign capabilities, and deliver greater benefits and returns to Australia and all Australians.

(10 May 2022):  The New South Wales Government has released its NSW 20-Year R&D Roadmap, mapping its long-term strategy for turning the state’s research and development capabilities into new world-leading industries and jobs.

(5 May 2022): AusBiotech welcomes new funding announced in the Victorian Government’s 2022/23 budget, including a new $20 million Equity Investment Attraction Fund, providing funding in return for an equity stake.

(3 May 2022):  Australia’s compelling medtech sector is taking centre stage in the new edition of Australasian Biotechnology, AusBiotech’s official journal, in anticipation of the upcoming AusMedtech 2022 conference.

(28 April 2022):  The highly-popular AusMedtech 2022 industry dinner is a hallmark of the AusMedtech 2022 programme and it is back to reignite and reconnect the medtech sector on Wednesday 25 May, during AusBiotech’s premier medtech conference.

(26 April 2022):  NSW Government has opened a registration of interest (ROI) process for an operator, to establish a commercial-scale GMP Pilot RNA manufacturing facility. This single site ecosystem has the ambition for leadership through manufacture across sRNA, mRNA and lipidnanoprotein encapsulation.

(21 April 2022):  AusBiotech is pleased to support Austrade’s BioKorea 2022 delegation to strengthen reciprocal relationships and showcase Australia’s investment opportunities and life sciences capabilities.

(19 April 2022):  AusBiotech supports Research Australia’s pre-Election statement on behalf of the Australian health and medical research sector, calling for reforms to  ensure research priorities better meet health system and population needs and maximises economic opportunities.

(14 April 2022):  AusBiotech supports call for the Federal Government to develop a National Competency Framework for Australia, endorsing the ARCS Australia Workforce & Capacity Summit White Paper (the Paper).

(12 April 2022):  AusBiotech is delighted to lead the Australian Pavilion at BIO 2022, as the world’s largest biotechnology congress returns in person to San Diego from 13-16 June 2022.

(7 April 2022): A new consultation reforming the research block grant funding framework, to increase collaboration between universities and industry, is open under the Department of Education, Skills and Employment.

(5 April 2022): Australia’s first Research & Development Tax Incentive (RDTI) Determination has been approved, offering certainty and transparency when claiming clinical trials activities.

(31 March 2022):  The federal Department of Health has launched a new ‘Biotechnology in Australia - Strategic Plan for Health and Medicine’ as part of the 2022-23 Budget.

(29 March 2022):  AusBiotech is launching AusBioNSW, a new peak industry membership body for NSW, to represent, connect, and promote NSW organisations doing business in and with the local, national and global life sciences economy.

(24 March 2022): AusBiotech joins global biotechnology peak industry bodies in their concern of the leaked ‘compromise text’ by World Trade Organization in negotiations on a proposed IP waiver for COVID-19 vaccines.

(22 March 2022):  The AusMedtech 2022 programme has launched, and delegates have until 28 March to register for early-bird registrations and access savings and the thought-provoking list of keynotes and panel sessions during Australia’s biggest week in medtech.

(17 March 2022): The West Australian State Government is offering a boost to life science companies, with start-ups and SMEs given the opportunity to apply for funding from two new programmes.

(15 March 2022): An Australian-first ‘gold standard’ framework has been developed to ensure health and medical discoveries can be fast-tracked to commercialisation, through a partnership between AusBiotech, the University of Sydney’s Faculty of Medicine and Health, and the University of Sydney Business School.

(10 March 2022): A Victorian Medtech Manufacturing Capability Program (MMCP) supporting the growth of its medtech and manufacturing sectors has opened.

(8 March 2022): In celebration of International Women’s Day, AusBiotech is offering practical and tangible opportunities to support gender equity of life sciences and supporting emerging female leaders via the ‘Big Sisters/Little Sisters’ programme and the ‘Women in Life Sciences (WILS) Luncheon’ in Sydney this week.

(3 March 2022): A new regulatory priority pathway has been proposed for novel biologicals, including human cell and tissue therapies, and AusBiotech is calling for feedback from affected members as it considers responding to the Therapeutic Goods Administration (TGA)’s consultation. 

(1 March 2022): Clarity and transparency are highlighted in AusBiotech’s recent submissions, as it responds to the Department of Industry, Science, Energy and Resources’ R&D Tax Incentive Determination and the Department of Health’s Prostheses List (PL) Reform consultations.

(24 February 2022): In recognition of the important role that industry plays in Australian clinical trials, a new Australian Clinical trials Alliance (ACTA) Industry Partnership Award has been launched.

(22 February 2022): The impacts of the reforms made to the Export Market Development Grants (EMDG) programme are now being felt, with grant amounts unexpectedly and significantly reduced.

(17 February 2022): Australian start-ups and early-stage companies developing US/European regulatory and reimbursement strategies are encouraged to engage in AusBiotech’s newest BiotechTalk webcast, and to learn about the processes that are essential for commercial success in Australia and internationally.

(15 February 2022): Feedback from AusBiotech’s medtech members is sought as the Department of Health proposes an ‘Abbreviated pathway’ within its newly proposed three-tiered approach to the assessment of Prostheses List (PL) applications.

(10 February 2022): The needs of biotech manufacturing have been reflected in the recommendations outlined in the Economics References Committee’s Inquiry into the Australian Manufacturing Industry’s report that was released this week.

(8 February 2022): The Bridge Program has opened its doors for 2022 applications, as it provides 100 mid-career professionals tailored training on the scientific, legal, financial, clinical, regulatory and reimbursement disciplines that are essential to pharmaceutical commercialisation.

(3 February 2022): Feedback is sought on the annual Therapeutics Goods Administration fees and charges consultation, as AusBiotech considers its response on behalf of the biotech industry.

(1 February 2022): Certainty and clarity are being offered for clinical trial activities under the R&D Tax Incentive, and AusBiotech is calling for Member feedback as it develops its response to the first draft determination released by the Department of Industry, Science, Energy and Resources.

(27  January 2022): Nirelle Tolsoshev, Managing Director for women’s health company Organon ANZ, has been announced as the keynote speaker for the Women in Life Sciences Luncheon in Sydney on 11 March 2022. Organon is the largest biopharmaceutical company dedicated to women’s health globally, and will share her experiences and insights into ‘amplifying her voice’.

(25  January 2022): Australian biotechnology manufacturers are invited to contribute to global benchmarking, with the 19th Annual Biopharmaceutical Manufacturing global survey underway.

(18  January 2022): There is still time to have your say on the sector’s draft Biotechnology Blueprint: A Decadal Strategy for the Australian Biotechnology Industry – a plan by the industry for the industry.

(18  January 2022): With the beginning of 2022, the pace picking up after the summer break, and the realities of our respective New Year’s resolutions settling upon us, AusBiotech starts the year with a recharged focus on leadership in policy and a resolution to continue committed advocacy for innovation in life sciences.

(16 December 2021):  To compile an accurate and truly national picture of the capability and capacity of Australia’s health security ecosystem, including end-to-end supply chains and workforce, the Australian biotech industry is invited to contribute to the National Health Security Resilience Assessment (NHSRA), that is closing with the year.

(16 December 2021):  The year has seen the biotech sector unite to progress and deliver, as it is recognised as an invaluable industry that continues to exhibit its strength in innovation and leadership. As the country and world has navigated ‘Covid-normal’ life, life sciences has gained great recognition for its health, economic and social value, as it focuses on the potential health products and services of tomorrow.

(14 December 2021):  Research Australia’s 18th Health and Medical Research Awards have been announced, and AusBiotech congratulates Professor Megan Munsie, Melbourne University, who was recognised for her ongoing advocacy work in stem cells. 

(9 December 2021): AusBiotech and Medicines Australia are thrilled to announce the annual NSW Women in Life Sciences Luncheon will be held in Sydney on Friday, 11 March 2022 in celebration of International Women’s Day, on 8 March.

(7 December 2021): AusBiotech congratulates Kate Quirke, CEO of Alcidion, who has been awarded a winner of the inaugural 2021 Brilliant Women in Digital Health. Kate Quirke is an AusBiotech member, was an AusMedtech 2021 keynote speaker, and is one of 25 women that have been recognised and celebrated for their outstanding achievements through the Telstra Health initiative.

(2 December 2021): AusBiotech is calling for thought leadership articles on innovative approaches, contributions or analyses to include in the April 2022 edition of the Australasian Biotechnology journal.

(30 November 2021): AusBiotech has welcomed The New Frontier - Delivering better health for all Australians – the final report delivered by the Parliamentary Inquiry into approval processes for new drugs and novel medical technologies in Australia.

(25 November 2021): Nominations have opened for the Prime Minister’s Prizes for Science, Australia’s most prestigious awards for outstanding achievements in scientific research and research-based innovation. The Science Prizes range between $50,000 - $250,000.

(23 November 2021): AusBiotech is seeking feedback from Members that may be impacted by potential TGA regulation changes on Mandatory Reporting of Medical Device Adverse Events by Healthcare Facilities in Australia.

(18 November 2021): AusBiotech is inviting session proposals for AusMedtech 2022, Australia’s premier medtech conference, to be held in person on 24 – 26 May next year. AusBiotech invites proposals for inspirational, cutting-edge session topics that will be at the forefront of the global medtech industry, including keynote presentations, discussion panels, and workshops.

(16 November 2021): Jointly delivering evidence to the Senate Inquiry on the Australian manufacturing industry last week, AusBiotech and Cell Therapies Ltd promoted Australia’s opportunity to harness the emerging regenerative medicine (RM), or cell and gene therapy, sector.

(11 November 2021): AusBiotech is calling for member feedback as it develops its response to the Australian Commission on Safety and Quality in Health Care’s clinical trials ‘National One Stop Shop’ consultation. Feedback will support the development of a single and nationally-focused health and human research approvals platform – the National One Stop Shop.

(9 November 2021): AusBiotech congratulates The University of Sydney’s Professor Anthony (Tony) Weiss AM, who has been presented with the $250,000 Prime Minister’s Prize for Innovation 2021. One of AusBiotech’s original members, Prof. Weiss has been recognised for his trailblazing research into accelerating and improving the repair of human tissue.

(4 November 2021): AusBiotech is inviting sector-wide feedback after releasing the draft Biotechnology Blueprint: A Decadal Strategy for the Australian Biotechnology Industry – a plan by the industry for the industry.

(1 November 2021): AusBiotech extends its enormous thanks to its Chair, Michelle Burke, as she retires from the board having successfully completed her nine-year tenure as Non-Executive Director, the maximum possible under the AusBiotech Constitution.

(28 October 2021): In recognition of the highest achievers in the Australian life sciences sector, the prestigious Industry Excellence Awards were announced today at the AusBiotech 2021 national conference, during Australia’s biggest week of biotech.

(26 October 2021): More than 900 Australian and global life science leaders are uniting virtually this week to celebrate, champion, and further the sector at AusBiotech 2021 and Australia Biotech Invest & Partnering 2021, Australia’s premier life science conferences, commenced today.

(21 October 2021): Food Standards Australia New Zealand is calling for feedback on its proposal to amend the definitions for gene technology and new breeding techniques, for clarity and to accommodate food produced by existing, emerging and future genetic technologies.

(19 October 2021): A newly-proposed standardised IP Framework is a long-supported idea, but should be voluntary, recommended a joint submission by Research Australia, AusBiotech, Medicines Australia and MTAA to the Department of Education, Skills and Employment’s recent consultation.

(14 October 2021): Bright ideas are wanted as the Biosecurity Innovation Program opens its expressions of interest, and seeks innovative technologies and approaches to keep Australia disease and pest free.

(12 October 2021): In less than two weeks, global keynote Dr Barney Graham will join Australia’s biggest week in biotech to share his lessons learnt during the COVID-19 pandemic and offer insights on the future of vaccinology.

(7 October 2021): The NSW Government has released its inaugural NSW Trade Statement, seeking to double exports to $200 billion by 2031, create more jobs, and support the State’s economic recovery. In order to reach its ambitious goals, 10 priority sectors have been identified, including health, biotech and medtech.

(30 September 2021): AusBiotech seeks Member feedback on the proposed standardised commercialisation agreements outlined in the Department of Education, Skills and Employment’s sector-agnostic consultation paper seeking to incentivise and increase partnerships between companies and universities.

(28 September 2021): A new Cell and Gene Catalyst (the Catalyst) is being established to capitalise on the opportunities that the burgeoning cell and gene sector can deliver to the Australian economy and society, and co-leads AusBiotech and Medicines Australia are seeking expressions of interest from industry partners interested in contributing to and supporting it.

(23 September 2021): Responding to the Economics References Committee’s Inquiry into the Australian Manufacturing Industry Australia’s opportunity to harness the important and emerging cell and gene therapies, or regenerative medicines (RM), sector was promoted through the joint submission of AusBiotech, Cell Therapies Ltd, Research Strategies Australia, and MTPConnect.

(21 September 2021): AusBiotech is seeking member feedback as it responds to the Department of Health’s Review of the National Medicines Policy (NMP).

(20 September 2020): It has come to our attention that a company is seeking to sell a contact list that is titled with AusBiotech’s name - in an unapproved manner.

(16 September 2021): AusBiotech and Medicines Australia released a joint statement urging the Australian Government to not support a proposed patent waiver for COVID-19 vaccines and therapies, as it will not help global vaccination.

(14 September 2021): Australia’s health innovators have united to release a statement supporting the introduction of a patent box, and welcoming the important initiative by the Australian Government. The collective statement made by Research Australia, AusBiotech, Medicines Australia, and the BioMelbourne Network asserts that with the right policy settings, a patent box will ensure Australian discoveries in health are developed here, ensuring Australia captures the opportunity for new industries and jobs in health innovation.

(9 September 2021): The R&D Tax Incentive (RDTI)’s administration model is being reviewed by the Board of Taxation (Board), a non-statutory Government advisory body, to identify opportunities for reducing duplication between the RDTI’s two administrators, to simplify administrative processes, and to reduce the compliance costs for applicants.

(7 September 2021):  Nominations are open for the Johnson & Johnson Scholars Award programme that aims to develop female leaders, and feed the talent pipeline. The $150,000 award sponsors women at critical points in their careers, in each of the disciplines: Science, Technology, Engineering Manufacturing, Math and Design (STEM2D).

(2 September 2021): To Members and other persons entitled to notice of Annual General Meetings (AGM) of AusBiotech Ltd, the 2021 AGM of AusBiotech Ltd will be held virtually and according to the AusBiotech Constitution on Friday 5 November 2021 at 12.30 pm - 1.30 pm AEDT to transact the following business...

(31 August 2021): Providing greater access to the upcoming Medical Research Future Fund (MRFF) Missions’ grant opportunities, the criteria to become an Eligible Organisation has been expanded to include public and private companies.

(26 August 2021): Nominations for the 2021 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards are open, and will recognise and celebrate life science leaders who are championing the sector and the Australian community.

(19 August 2021): A new Nasdaq Board Diversity Rule encouraging minimum board diversity has been approved by the U.S. Securities and Exchange Commission. Board diversity is well-recognised as making good business sense and this Rule is another important example of efforts to foster an inclusive industry culture, and an opportunity for biotech to attract the best and brightest talent from diverse backgrounds.

(19 August 2021): The impact of three tax concessions aimed at increasing venture capital investment in Australia and upskilling venture capital fund managers are being evaluated by the Australian Government, after being announced five years ago.

(17 August 2021): AusBiotech is calling on its Membership as it searches for an experienced and influential successor as its next non-executive Chair.

(17 August 2021): Through its submission to Treasury, AusBiotech has called for a patent box design that works for the very industry it is intended to incentivise, and takes account of the unique characteristics of medical and biotechnology development.  

(10 August 2021): Consultation on the Treasury’s draft legislation for further reforms of Australia’s Employee Share Scheme (ESS) has opened, and AusBiotech is seeking feedback from Members that may be impacted.

(5 August 2021): AusBiotech calls for feedback on its six key recommendations in response to the Treasury discussion paper on the Australian patent box policy design.

(3 August 2021): The AusBiotech 2021 programme has been released, and features global thought-leaders, and pressing and emerging topics to drive the Australian biotech sector forward. Opening the largest annual biotech gathering for the Australian life science industry, Millis Oration keynote Professor Sharon Lewin AO, Director, The Peter Doherty Institute for Infection and Immunity, will address HIV to COVID-19: what history has taught us about our response to pandemics.

(29 July 2021): A draft strategic roadmap has been released for a new regenerative medicine (RM) Catalyst, and sector feedback is sought from those interested in the future of RM in Australia.

(27 July 2021): AusBiotech is seeking feedback from Members that may be impacted by proposed TGA regulation changes through the Proposed refinements to the regulation of medical devices that are substances introduced into the human body via a body orifice or applied to the skin.

(22 July 2021): ANDHealth’s annual digital health survey is open, and input from digital health innovators and companies is being called for to help identify gaps, challenges and opportunities in digital health commercialisation.

(20 July 2021): Large-scale medical product manufacturers in Australia are being invited to apply for Federal funding through its “Manufacturing Collaboration” stream, under the Modern Manufacturing Initiative (MMI). Co-funded grants from $20 million to $200 million are available, from a total funding pool of $800 million. 

(15 July 2021): Nominations are being called for Austrade’s 59th Australian Export & Investment Awards, in recognition and celebration of businesses achieving export success.

(13 July 2021): Australian regenerative medicine company PolyNovo stars in a new, global BBC biotech series as one of just 27 companies chosen worldwide, and the only Australian company. The video is an important indication of Australia’s position in the strong international biotech community.

(8 July 2021): Agri-biotech companies across all mainland Australian States now stand in-line with their global competitors, after the expiration of the NSW Government’s 18-year moratorium on genetically-modified crop innovations commenced this month.

(6 July 2021): Consultation on the design of the Australian patent box has been opened by Treasury, after the Federal Treasurer announced the policy for the medical and biotechnology sectors during the 2021 Federal Budget.

(1 July 2021): AusBiotech has joined BIO, the UK BioIndustry Association, and more than 290 other global biotech company leaders as they unite in their concern of the ongoing risk to international IP protection that is before the World Trade Organization (WTO).

(29 June 2021): The Victorian Government is calling for nominations for Victoria's prestigious science research awards.

(24 June 2021): mRNA Victoria, in collaboration with AusBiotech and BioMelbourne Network, is seeking Victorian-based companies with relevant experience in mRNA or RNA-related manufacture, supply chain and systems support to submit their expression of interest (EOI) for its Industry Panel.

(22 June 2021): Responding to advances in science, revised Guidelines for Stem Cell Research and Clinical Translation have been published by the International Society for Stem Cell Research.

(17 June 2021): The AusBiotech-led Team Australia delegation featured in the top four largest pavilions present at BIO Digital 2021 this week, where it proudly flew the virtual Australian flag and showcased Australia’s capabilities to a global audience.

(15 June 2021): AusBiotech has welcomed the first step towards a national front door for clinical trials, as the Australian Commission on Safety and Quality in Health Care announces scoping is underway on a national one-stop-shop and consequently, a ‘National Clinical Trials Front Door’.

(10 June 2021): Medtech stakeholders can be kept abreast of how the establishment of a new Australian Unique Device Identification (UDI) system will effect their companies through the Therapeutic Goods Administration’s upcoming webcast series.

(8 June 2021): AusBiotech is inviting its Members to join it in signing a global, open letter in opposition to the ongoing risk to international IP protection that is before the World Trade Organization (WTO).

(4 June 2021): Two of Australia’s premier life science industry events are heading to Western Australia in 2022, for the first time in more than 15 years. AusBiotech 2022 and Australia Biotech Invest & Partnering 2022 will showcase Australian life sciences, and deliver the biggest week in biotech for the year.

(1 June 2021): AusBiotech is calling for session proposals and speakers for Australia’s largest life sciences event of the year: AusBiotech 2021, to be held 25 - 29 October. Running for more than 35 years, Australia’s premier conference is developed by industry, for industry, and celebrates and champions our sector.

(27 May 2021): AusBiotech is bolstering its capabilities, appointing two new members to its team: Director, Industry Policy and Advocacy: and Industry Communications Coordinator. These roles are critical for AusBiotech as it drives the sector forward during a time when biotech is being recognised for the economic and social benefits it delivers.

(25 May 2021): Nutromics took home the coveted ‘Best Translational Research’ award at AusMedtech 2021’s Early-Stage Investment Forum, after winning the pitching event judged by an expert investment panel.

(20 May 2021): AusBiotech is celebrating International Clinical Trials (CT) Day today, 20 May, recognising Australia’s leadership and excellence in CTs and the important role it plays in Australia’s economy, healthcare and social fabric, with benefits far beyond helping develop new treatments.

(18 May 2021): AusBiotech presented today at the Parliamentary Inquiry into approval processes for new drugs and novel medical technologies in Australia, highlighting the long-term and stable biotech policy incentives needed to support and sustain R&D for treating rare diseases and conditions, where there is high and unmet clinical need.

(13 May 2021): Announcements in the 2021 Federal Budget are backing biotech and demonstrating the Government’s ongoing recognition of biotechnology as a long-term social and economic driver that will enhance Australia’s competitiveness, and keep us at the cutting edge of science and innovation.

(11 May 2021): The global biotech industry is united in its drive for equitable access to COVID-19 vaccines, but the proposal to waiver IP protection that is before the World Trade Organization (WTO) will not overcome the barriers preventing access.

(11 May 2021): It has come to our attention that a company is seeking to sell a contact list that is titled with AusBiotech’s name and logo - in an unapproved manner.

(6 May 2021): In less than two weeks hundreds will gather for Australia’s premier medical technology conference, which will reconnect key stakeholders of the Australian devices and diagnostics sector to help reimagine the industry during a changing landscape. Business partnering will open in less than one week.

(4 May 2021): AusBiotech is inviting expressions of interest from its corporate members for its new virtual pitching series, BiotechPitch. Its new platform will profile Australian companies to investors internationally, and will feature expert industry speakers and commentators offering capital insights and market updates.

(29 April 2021): Australia’s dynamic medtech sector is taking centre stage in the May edition of Australasian Biotechnology, AusBiotech’s official journal, in anticipation of the upcoming AusMedtech 2021 conference.

(27 April 2021): The impact of Victorian Government’s investment in health and medical research has been revealed through its newly released report ‘Creating a healthy future.’

(22 April 2021): AusBiotech is fostering its international connections with biotech and medtech companies and demonstrating why Australia is a global leader within the sector, through its support of the Australian delegation and pavilion at BioKorea 2021.

(20 April 2021): AusBiotech announced today the appointment of Dr James Campbell as an AusBiotech Director, contributing strong commercialisation and capital-raising expertise to the Board.

(15 April 2021): CSL Behring and Cicada Innovations’ new Plasma Protein Purification Challenge seeks to tackle some of the biggest challenges in plasma protein production, and to save and improve lives.

(13 April 2021): AusBiotech united voices across the biotech pipeline as it responded to the University Research Commercialisation (URC) consultation and provided views on how any new scheme must be set in the context of a strategic long-term national objective.

(8 April 2021): AusBiotech is inviting companies to be prominently profiled at its Team Australia digital pavilion at BIO Digital 2021. As the industry’s independent voice, AusBiotech has led the Australian delegation to BIO for more than a decade, and Australia’s strong presence will continue to be felt at BIO Digital 2021.

(6 April 2021):  Grants between $25,000 and $480,000 for female founded start-ups are being provided to expand into domestic and global businesses.

(1 April 2021): Feedback essential for commercialising early-stage projects and technologies is being offered by an expert and investor group at AusMedtech’s Early Stage Investment Forum. Early-stage projects are invited to apply for the AusMedtech 2021 Early Stage Investment Forum, with submissions due 9 April 2021.

(30 March 2021): As plans are being finalised for the medtech week of the year, early bird registrations are still open until 3 April for AusMedtech 2021.

(25 March 2021): A new model to encourage university research commercialisation (URC) is being developed, and Members are invited to an AusBiotech virtual roundtable as it develops its response. The Department of Education, Skills and Employment’s consultation paper explores possible mechanisms to incentivise and increase partnerships between businesses and universities.

(23 March 2021): AusBiotech has responded to changes proposed by the Office of the Gene Technology Regulator (OGTR) to the Gene Technology Scheme, that seek to modernise and future-proof the risk-management framework.

(18 March 2021): The NSW Government has announced access will continue for approved genetically modified crop innovations, as it will not seek to continue an 18-year moratorium that is due to expire on 1 July 2021.

(16 March 2021): The biggest gathering of Australia’s biotech industry, AusBiotech 2021, will now be offered through a predominantly virtual format, after AusBiotech shifted its plans and support to bring the planned in-person event to Brisbane moving to October 2023.

(11 March 2021):  A new expert Leadership Forum to drive the development of the industry’s Biotech Blueprint, the sector’s decadal framework, has been announced. The Leadership Forum includes key industry leaders that represent ...

(9 March 2021): The NSW government has launched its Accelerating R&D in NSW Action Plan, with key themes aligning to the industry needs highlighted in an AusBiotech NSW roundtable last year.

(4 March 2021): An inspiring line-up of Australian and global keynotes and panels has been revealed as the AusMedtech 2021 conference programme is launched. AusMedtech 2021: Reimagine and reconnect provides virtual half-day sessions across five days, 17 – 21 May, that represent Australia’s medtech industry.

(2 March 2021): AusBiotech welcomes the Government’s support of the biotech industry as it opens the first round of funding for bio-manufacturing and launches its Medical Products’ National Manufacturing Priority road map.

(25 February 2021): AusBiotech is seeking feedback from Members on proposed changes to the Gene Technology Scheme (the Scheme) that may impact companies and early research working with GMOs. While the Scheme has previously focused on biotech’s agricultural application, attention is now turning to managing risk in emerging technologies, such as gene therapies, with proposed changes related to definitions, risk-proportionate regulation, and streamlining regulation.

(23 February 2021): The Bridge Program is currently accepting applications for its next cohort, and provides specific training on the scientific, legal, financial, clinical, regulatory and reimbursement disciplines that are essential to pharmaceutical commercialisation.

(18 February 2021): AusBiotech has submitted comment on the Department of Health’s Prostheses List (PL) consultation on behalf of members, advocating for maintained access to new innovation in order to achieve good outcomes for patients through timely access to the medical devices they need.

(16 February 2021): With the news of Cell Therapies’ regenerative medicine (RM) manufacturing capabilities expanding, the mapping of Australia’s RM manufacturing capability that the AusBiotech-led RM Catalyst Project is doing is highlighted.

(11 February 2021): Gender diversity on biotech boards has increased, with a recent review of ASX-listed biotech companies revealing an average representation of 26 per cent for FY20. AusBiotech is encouraged that this is a step in the right direction as equality becomes a reality, however more work is required if biotech boards are to meet the AICD goal of 30 per cent.

(9 February 2021): AusBiotech is seeking comment from members affected by the Department of Health’s Prostheses List consultation paper: Options for reforms and improvements to the Prostheses List (PL).

(4 February 2021): Early bird registrations have opened today for AusMedtech 2021, Australia’s premier medtech conference, that will be delivered virtually during 17 – 21 May 2021.

(2 February 2021): Expressions of interest from industry leaders are sought to join AusBiotech’s new expert forum to drive the development of the industry’s Biotech Blueprint, the sector’s decadal framework.

(28 January 2021): The National Medical Countermeasures Initiative has invited the life sciences industry to help shape the future of Australian health security policy. The Initiative is developing a comprehensive national picture of Australia’s capability and capacity to conduct research, development, manufacturing and distribution of products and services that are essential to the nation’s health security.

(21 January 2021): AusBiotech’s international partnerships have been extended, with new Memorandums of Understanding (MoU) signed with major international industry associations to support collaboration efforts.

(19 January 2021): As we enter a new year and reflect on the past 12 months, the metrics show a positive and resilient outcome for the industry with the highest capital raising for life science companies on record.

(14 January 2021):  Completing the ‘Update online roadshow’ AusBiotech members from Queensland and Western Australian are invited to hear the latest information from their State Government representative at AusBiotech’s Industry Update, which aims to grow and support the biotech industry.

(12 January 2021): As the country returns after the festive break and the realities of ‘COVID-normal’ and the respective New Year’s resolutions settle on us, AusBiotech starts the year focused on leadership in policy, and a resolution to continue committed advocacy for innovation in life sciences.

(22 December 2020):  2020 has been an unforgettable year, with the biotech community’s strong contribution to the global healthcare system and to Australia’s economy shining brightly through the many challenges being faced professionally and personally.

(17 December 2020): Applications are open for round 9 of the NSW Government’s Medical Devices Fund (the Fund). More than $8 million in competitive funding is available to support investment in the development and commercialisation of medical devices, and related technologies.

(15 December 2020): Save the date for AusMedtech 2021, Australia’s premier medtech conference, that will be delivered virtually during 17 – 21 May 2021.

(10 December 2020): AusBiotech is calling for feedback on the draft goals of the Biotech Blueprint: Australia’s life science industry’s decadal framework. These goals will set the structures for the broader strategy that will underpin and drive industry growth through to 2030.

(8 December 2020): New guidance on personalised medical devices (PMD), including 3D printed devices, has been released by the TGA. New regulatory requirements will apply under the framework from 25 February 2021.

(3 December 2020):  Australian manufacturers invited to contribute to global benchmarking, with the 18th Annual Biopharmaceutical Manufacturing global survey underway.

(1 December 2020): AusBiotech is set to showcase the globally-recognised strength of the Australian clinical trials sector during JP Morgan week in January 2021.

(26 November 2020): Clinical trials, immediate initiatives and long-term strategies to support life sciences at a State and national level were highlighted at AusBiotech’s SA Industry Update.

(24 November 2020): AusBiotech is preparing for Australia's life science industry’s future, and the sector is invited to have their say on the draft goals that will underpin and drive its decadal strategy: the Biotech Blueprint.

(19 November 2020): During World Antimicrobial Awareness Week, AusBiotech celebrates the leading work of the Australian life sciences industry as it prepares for the role it may take in addressing antimicrobial resistance (AMR), and the opportunities and barriers ahead of us.

(17 November 2020): The Clinical Trial Exemption (CTX) scheme - one of the two avenues available for trials of unapproved therapeutic goods in Australia - has been renamed as the Clinical Trial Approval (CTA) scheme.

(12 November 2020): AusBiotech has used its submission on the Department of Industry, Science, Energy and Resources’ Patents Accessibility Review to support efforts that ensure the patent system represents an accessible and useful resource for SMEs.

(5 November 2020):  AusBiotech welcomes and congratulates Dr Cathy Foley, as Australia’s newly-appointed  Chief Scientist.

(5 November 2020):  A new consortium preparing for Australia’s regenerative medicine (RM) future has been announced at AusBiotech + Invest 2020. AusBiotech will lead the consortium of seven partners as industry prepares to thrive and drive benefits to Australia’s economy and the health of its people, after it received funding through MTPConnect’s Project Fund Program.

(3 November 2020): The prestigious Industry Excellence Awards were announced at the AusBiotech + Invest 2020 national conference, during the biggest week in biotech. The AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards recognise and celebrate life science leaders who are championing the sector and the Australian community through the worst pandemic and greatest collaboration seen in the sector.

(29 October 2020):  AusBiotech announced the election of Linda Peterson as a Director at its Annual General Meeting yesterday – an addition that will bring 30 years’ experience from across the breadth and depth of the sector.

(27 October 2020): A new level of global insight and perspective will be offered this week at AusBiotech + Invest 2020, as Australia’s largest life sciences conference assembles virtually for biotech’s biggest week of the year. 

(22 October 2020): CSL have announced the winners of their two five-year $1.25 million fellowships, with research investigating new ways to combat health challenges of global significance: cancer and infectious diseases.

(20 October 2020): AusBiotech is seeking comment from affected members on two TGA consultations on medical devices: options for introducing a UDI system, and enhancing reporting of adverse effects.

(15 October 2020): A new cross-industry report has been released today, delivering a better understanding of the life sciences sector’s workforce needs and skills gaps.

(13 October 2020): The fourth edition of the Official Australian Reference Guide to Agricultural Biotechnology and GM Crops (the Guide) has been launched by the Agricultural Biotechnology Council of Australia (ABCA).

(8 October 2020): New guidance on faecal microbiota transplant (FMT) products has been released by the TGA. The two documents include a FMT product Standard that specifies the minimal requirements for donor and product screening; and specific guidance on manufacturing requirements.

(6 October 2020): AusBiotech applauds Minister for Health, Greg Hunt’s announcement of $12 million to ‘digitise, transform and modernise’ the TGA’s business systems and infrastructure.

(1 October 2020): AusBiotech welcomes support for medical manufacturing as the Prime Minister, Scott Morrison, announces its manufacturing plan ahead of next week’s Federal Budget. However, the industry advocate remains concerned that overall support will be reduced if the Bill to cut the R&D Tax Incentive (RDTI) moves ahead. 

(29 September 2020): To guide the Medical Research Future Fund (MRFF) Australian Medical Research and Innovation Priorities for 2020–2022, a national consultation process is underway by the Department of Health.

(24 September 2020): To inform the ongoing implementation of a tele-trial model, feedback is sought from sponsors that have experience in implementing tele-trials in Australia or are actively considering utilising tele-trials.

(17 September 2020): AusBiotech calls on its Members for feedback on its response to a new Parliamentary Inquiry that is considering the “approval processes for new drugs and novel medical technologies in Australia.” The Inquiry has a particular focus on those for the treatment of rare diseases and conditions where there is high and unmet clinical need.

(17 September 2020): Experts are noting that healthcare is faring well on the investment ‘front’, recession-proof even, but the full scale of the impact of COVID-19 is yet to be realised, especially for life sciences companies requiring substantial investment from public and private sources to commercialise medical research.  

(16 September 2020): It has come to our attention that a company is seeking to sell a contact list that is titled with AusBiotech’s name - in an unapproved manner.

(15 September 2020): Guiding principles on optimising digital technology for executing clinical trial research agreements (CTRAs) using eSignatures has been released in a new position statement: Electronic signatures and clinical trial research agreement execution in Australia.

(10 September 2020): Australia has been amongst the globe’s lesser COVID-19-impacted countries, providing the opportunity to start and continue clinical trials and medical research through the pandemic.

(10 September 2020): Nominations for the 2020 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards are open, and will recognise and celebrate life science leaders who are championing the sector and the Australian community through the worst pandemic and greatest collaboration seen in the sector.

(8 September 2020): The focus on building resilience in global trade and supply chains has increased in relevance and urgency, and Austrade and the Global Trade Professionals Alliance (GTPA) invite you to complete a survey to better understand industry needs.

(3 September2020):  AusBiotech welcomes its new industry Advisory Group Chairs: Dr Megan Robertson, St Vincent's Hospital Melbourne, Chair of the AusBiotech Clinical Trials Adivsory Group; and Dr Amanda Gillon, Bioscience Managers, Chair of the AusBiotech Investor Advisory Group.

(1 September2020): The significant role that the biotechnology industry can play in our country’s economic future and healthcare, when supported through the right policy levers and support, was highlighted in AusBiotech’s pre-budget submission to the Australian Government Treasury.

(27 August 2020): AusBiotech will roll out a virtual Industry Update roadshow over the coming months, to update members on Federal and state-specific issues and hear about support and programmes from state governments.

(26 August 2020): To Members and other persons entitled to notice of Annual General Meetings (AGM) of AusBiotech Ltd, the 2020 AGM of AusBiotech Ltd will be held virtually and according to the AusBiotech Constitution during the AusBiotech national conference on Wednesday 28 October 2020 at 12.30 pm - 1.30 pm to transact the following business:

(25 August 2020): It is with sorrow that AusBiotech acknowledges the passing of Living Cell Technologies (LCT) Founder, Emeritus Professor Sir Robert Elliott.

(20 August 2020): The first tranche of the proposed reforms to Australia’s foreign investment regulation regime has been released, with the Government advising that it expects that the overwhelming majority of investments will not be called in for review.

(18 August 2020): Global fundraising by cell and gene therapy developers more than doubled during the first half of 2020, compared with the first half of 2019.

(13 August 2020): In order to seek early access to and delivery of safe and effective COVID-19 vaccines and treatments, the Australian Government Department of Health is auditing Australia’s vaccine and treatment manufacturing capability and capacity. Organisations already regulated or likely to seek regulation through the Therapeutic Goods Administration are requested to respond.  

(11 August 2020): New tools and resources have been developed by IP Australia to support small to medium enterprises (SMEs) access the intellectual property (IP) system and to navigate the patent process.

(6 August 2020): AusBiotech congratulates the founders of medtech company SpeeDx for winning the coveted Clunies Ross Award for Innovation, in recognition of their dedication to fostering entrepreneurship and innovation in Australia.

(4 August 2020): Register by Wednesday 5 August to save up to $200 on registration to AusBiotech + Invest 2020 –Australia’s biggest week in biotech that in October will feature the event you know and trust, with new opportunities for global delegates and speakers, and a new level of global insight and perspective.

(30 July 2020): A new Austrade insights paper has been released updating the life sciences sector on how to fast track approvals in China’s drugs market to unlock pharma prospects.

(28 July 2020): Amended legislation will facilitate exports for the emerging medicinal cannabis and hemp industries, and better support access to international markets for the agritech industries.

(23 July 2020): AusBiotech congratulates its members that are amongst recipients of the third round of the $18.8 million funding from the BioMedTech Horizons (BMTH) program, an initiative of the Medical Research Future Fund (MRFF).

(21 July 2020):  The NSW Government is investing $3 million in NSW’s innovation ecosystem to accelerate to market products that are addressing the impact of COVID-19.

(16 July 2020): More than 20 global pharmaceutical companies have collectively pledged to invest nearly US$1 billion through a new Antimicrobial resistance (AMR) Action Fund. It will invest in smaller biotech companies and provide industry expertise to support the clinical development of novel antibiotics.

(14 July 2020): Australia’s technology industry should aim to double in size and output by 2030, highlights the Australian Investment Council’s (AIC) new report. The significant benefits of this would flow to almost every industry in Australia through growth, improved productivity and new high-value job creation.

(9 July 2020): In order to better understand how innovation perspectives and actions are changing across Australian business leaders, as we adjust to a new post-COVID operating environment, KPMG’s Digital Delta Innovation Strategy team invites you to complete a short survey.

(7 July 2020): As the Senate Inquiry considering the Research and Development Tax Incentive (RDTI) Bill takes its final evidence and deliberates ahead of it August reporting date, AusBiotech stands steadfastly united with industry in its call for the Bill to be scrapped.

(2 July 2020): AusBiotech commends comments from Health Minister, Greg Hunt, who noted the “golden opportunity” for Australia to be a world leader in clinical trials and medical research.  

(30 June 2020): AusBiotech is calling for innovative approaches, contributions or analyses to include in its October 2020 edition of the Australasian Biotechnology journal.

(25 June 2020): Early stage researchers are invited to apply for Takeda Pharmaceutical’s A$100,000 grant programme.

(23 June 2020): Nominations are open for the 2020 Peter Wills Medal in recognition of an individual who has made an outstanding, long-term contribution to building Australia’s international reputation in health and medical research and fostering collaboration for better health.

(18 June 2020): The $250 million Victorian Business Growth Fund (VBGF) is now open to support long term growth opportunities for businesses, and boost employment and economic development across the State.

(16 June 2020): Expected changes to medical device regulations have been delayed as a result of the COVID‑19 impacts being faced across the domestic and global medical device industry.

(9 June 2020): Companies are being asked to identify the current, emerging, and future skills shortages the life sciences sector is facing in order to address the gaps and drive greater sector growth across Australia.

(9 June 2020): Health minister Greg Hunt will be joining the BIO Digital 2020 International Plenary, addressing 'How are global leaders collaborating to combat the pandemic?'

(4 June 2020): Australian manufacturing companies responding to COVID-19 will have greater access to potential partners and customers through an industry matchmaking site, backed by the Morrison Government.

(2 June 2020): A roadmap of recommendations to minimise and mitigate the COVID-19 impacts on the biotechnology industry, and to facilitate the fastest recovery possible, has been submitted by AusBiotech to the National COVID-19 Coordination Commission (NCCC).

(28 May 2020): AusBiotech is calling for expressions of interest from Australian therapeutic and medtech member companies that are interested in featuring in a new biotech BBC series. This web-series works to challenge viewers’ perceptions and bring more understanding to biotech, showcasing how it is bringing solutions to global challenges.

(26 May 2020): LiVac was awarded a $10,000 People’s Choice award from Medtronic at AusBiotech’s BiotechTalks webcast, after winning a pitching event as part of the Eureka Live programme.

(21 May 2020): The Australian Government has given approval to proceed with implementation of enhanced transparency measures for prescription medicines, in response to public demand for more information on prescription medicines that are under evaluation.

(19 May 2020): AusBiotech welcomes Michelle McMurry-Heath, immunologist and former FDA official, who will succeed Jim Greenwood as new CEO of Biotechnology Innovation Organization (BIO) on 1 June 2020.

(14 May 2020): The National Collaborative Research Infrastructure Strategy (NCRIS) has developed a package of support for clinical professionals and researchers working in response to COVID-19.

(12 May 2020): Industry has united in an open letter to call to back Australian life science companies to keep their priceless talent during COVID-19.

7 May 2020: It has come to our attention that a company is seeking to sell a contact list that is titled with AusBiotech’s name - in an unapproved manner.

7 May 2020: CSL have announced the development of a new investigational product, with the potential to treat people with serious complications of COVID-19, particularly those whose illness is progressing towards the need for ventilation.

5 May 2020: Despite previous guidance from Government, the ATO has today advised AusBiotech that its application for a class ruling on the JobKeeper payment for pre-revenue companies cannot be made by the Tax Commissioner.  

30 April 2020: AusBiotech is seeking comment from affected members on a TGA consultation on proposed measures to clarify the boundary for software-based products that are captured under the regulatory framework for medical devices in Australia.

28 April 2020: Almost 20 companies joined AusBiotech’s policy roundtable to discuss opportunities in NSW with the Hon. Gabrielle Upton MP, Parliamentary Secretary to the Premier, who has been tasked with accelerating R&D investment.

23 April 2020: A new suite of teletrial standard operating procedures (SOPs) have been developed to assist sites to conduct teletrials in accordance with Good Clinical Practice (GCP), and any relevant local and national requirements.

21 April 2020: The Therapeutic Goods Administration (TGA) is working to keep industry informed with the latest information on medicines and medical devices in light of COVID-19 and information is being updated rapidly.

16 April 2020:  AusBiotech’s survey of members is providing an insight into the current challenges facing the biotech industry, as it pivots into new working practices and adjusts to the new reality.

14 April 2020:  AusBiotech will seek a class ruling on the Jobkeeper payment scheme from the Tax Commissioner, formally requesting that biotech companies be included due to their unique business model and their contributions to society and the economy.

9 April 2020: With health service organisations’ priorities and resourcing being affected by the current COVID-19 pandemic, the National Clinical Trials Governance Framework (Governance Framework) pilot has been extended.

7 April 2020:  With the biotechnology at the forefront of the COVID-19 response, especially in clinical trials for new therapies and vaccines, AusBiotech is calling on the Government to support pre-revenue companies with access to funds including the JobSeeker payment and early payment of the R&D Tax Incentive refund.

2 March 2020:  AusBiotech is pleased to announce that Dr Megan Baldwin, CEO and Managing Director of Opthea Limited, has been appointed as AusBiotech’s new Deputy Chair, following Michelle Burke becoming the Chair in late February.

31 March 2020:  Amid the sudden shock of COVID 19 to our society and economy, AusBiotech has joined the growing chorus of businesses calling for the Government to fast track RDTI cash refunds and drop the proposed plans to cut the landmark programme. 

26 March 2020:  In support of the clinical trials sector and in recognition of the challenges the health system faces during the COVID-19 pandemic, a position statement has been developed by the Research and Development TaskForce (RDTF), sponsored by AusBiotech, Medicines Australia, and the Medical Technology Association of Australia, together with respective memberships.

24 March 2020:  The Australian Government has announced $13 million to fast-track research and development of treatments for COVID-19 (coronavirus), and has opened the Boosting Female Founders Initiative with $6 million to launch and scale businesses into domestic and global markets.

19 March 2020:  A free webinar is being provided for the Australian clinical trials sector to discuss the impacts of COVID-19 (coronavirus).

17 March 2020:  AusBiotech lodged two submissions strongly opposing the Research and Development Tax Incentive Bill that is in front of a Senate Inquiry, after repeatedly urging that the reform legislation be delayed until the details, mechanics and impacts are better understood and can be mitigated.

12 March 2020:  Two new seminars have been announced as part of the AusBiotech Regulatory Roadshow, which has been designed to help SMEs, early-stage companies, and clinicians understand the medical device evidential requirements of both regulators and payers in the US healthcare market.

10 March 2020: Australian life science companies are being encouraged to apply for the Start-up Stadium, an international pitching initiative that will put them on the global stage and in-front of investors at the 2020 BIO International Convention (BIO).

5 March 2020:  In advance of International Women’s Day, more than 440 life science leaders will gather tomorrow for AusBiotech’s annual New South Wales Women in Life Sciences Luncheon. This year's theme, inspire, influence, involve, conveys a movement that is beyond gender, and increasing the number of female leaders in senior positions is a conversation everyone should be participating in.

3 March 2020:  AusBiotech has published a new fact sheet to contribute to evidence-informed discussions about human germline genome editing.

27 February 2020: Feedback is sought on the draft National Clinical Trials Governance Framework (Governance Framework) that has been finalised by the Australian Commission on Safety and Quality in Health Care (the Commission).

25 February 2020:  AusBiotech has announced that a new Chair has been appointed to its Board following the decision of its current long-serving Chair, Julie Phillips, CEO, BioDiem, to step down from the AusBiotech Board. Michelle Burke, Principal and Director, Indigo Advisory and current Deputy Chair, AusBiotech, will take up the role. The Board also farewells Barry Thomas after five years, following his retirement from Cook Medical.

BiotechDispatch (25 February 2020): Further expansion for consultancy Biointelect with the company opening a Melbourne office and adding additional expertise

20 February 2020:  Medtronic Australasia is calling for innovative companies across Australia and New Zealand that are looking to scale-up, as it launches its new Eureka LIVE programme at AusMedtech 2020.

18 February 2020:  The Department of Health is currently seeking expressions of interest to assist with grant review and assessment processes for the Medical Research Future Fund (MRFF) Rural, Regional and Remote Clinical Trial Enabling Infrastructure (RRRCTEI) Grant Opportunity.

13 February 2020:  Western Australia is preparing to become a world-leading life sciences hub of note, announcing the formation of an Industry Reference Group to drive the development of a new five-year life sciences action plan.

11 February 2020:  Australian biotech companies are at the forefront of global responses following the infection of thousands from the coronavirus, which is continuing to rapidly spread across the world, and a summer of catastrophic fires across Australia.

6 February 2020:  A new report revealing more work is needed on diversity and inclusion in the biotech sector has been released by the US Biotechnology Innovation Organisation (BIO). Baseline findings on representation show that responding companies have not achieved gender parity.

4 February 2020:  AusBiotech is calling for session proposals and speakers for the life sciences event of the year: AusBiotech 2020, to be held in Melbourne, 28 - 30 October. AusBiotech 2020 is delivered by industry, for industry.

30 January 2020:  Australian manufacturers invited to contribute to global benchmarking, with the 17th Annual Biopharmaceutical Manufacturing global survey underway.

28 January 2020:  AusBiotech is pleased to continue its partnership with CSIRO, connecting the sector by delivering 2020’s first BioCheers events in Victoria, New South Wales, and Queensland during February. This partnership is significant as AusBiotech continues strengthening its alliances with key stakeholders in the industry, and connecting the pipeline of inventors who work in the sector.

23 January 2020:  Regenerative medicine is poised for continued expansion in 2020, after the latest global industry briefing reveals another year of significant growth, and total global financings the second highest yet.

21 January 2020:  AusBiotech has launched the 2020 CEO Industry Position Survey, asking leaders of biotechnology companies for their views and policy priorities of our Australian life sciences sector.

16 January 2020:  The TGA is seeking feedback on two consultations, into the guidelines for the export of therapeutic goods from Australia, and the proposed adoption or non-adoption of a multitude of EU and ICH guidelines.

14 January 2020:  The New Year has dawned with news that the strength and success of the biotech sector delivered over the past year, and continued over Christmas. Over $1.06 billion total capital was raised by Australian biotech across the year (Bioshares), ending with a late December announcement from Ellex Medical Lasers of a $100 million deal.

10 January 2020:  The AusBiotech Team’s thoughts are with members and others who have been affected through the unrelenting Australian bushfires. We are in awe of the incredible dedication of our firefighters and the resilience being shown across communities, and broken-hearted at the loss that has resulted.

19 December 2019:  This year has seen another strong performance in biotech: AusBiotech advanced a resolute advocacy programme, saw a Federal election, engaged members and parliamentarians at a CEO Policy Forum where an Australian Biotechnology 2030 Plan was announced, and launched new quarterly policy updates.

17 December 2019:  AusBiotech and Medicines Australia are delighted to
announce the annual NSW Women in Life Sciences Luncheon 2020 will be held in Sydney ahead of International Women’s Day, on 6 March 2020.

12 December 2019:  A final call has been made for nominations of leading science and technology entrepreneurs for the Clunies Ross Awards.

10 December 2019:  AusBiotech has released a new report illustrating for the first time the disproportionately-negative effects that the biotech sector faces above other innovative industries, by the proposed changes in the new Research and Development Tax Incentive (RDTI) Bill.  

5 December 2019:  Views are being sought on a discussion document designed to advance industry’s role in the future of genomics in Australian healthcare.

03 December 2019:  NSW Health’s Medical Devices Fund (the Fund) has opened its latest round, with $8 million available to support local innovation on its journey to market. The Fund invests in the development and commercialisation of new and innovative medical devices and related technologies in NSW, that may have a global benefit.

28 November 2019:  A new Australian Register of Clinical Registries has been announced to facilitate better collaboration and awareness of registry activity across Australia. The national landscape for clinical quality registries (CQRs) is undergoing significant change as their value is being increasingly recognised and health information technology continues to develop.

26 November 2019:  AusBiotech is calling for innovative approaches, contributions or analyses to include in their 2020 Australasian Biotechnology journals. AusBiotech is welcoming abstracts from valued members on medtech, digital health, and therapeutic trends and discoveries to illustrate the industry’s achievements and challenges being faced.

21 November 2019:  More biotech companies are moving into the ASX200, with two new companies recently joining the list: PolyNovo (PNV) and Avita Medical (AVH). This movement demonstrates the healthy biotech pipeline in Australia, with more SMEs progressing through as the life sciences sector grows and matures.

19 November 2019:  For the first time since its inception in 2000, the VISION leadership programme will be held in Australia in February 2020. Targeting current and emerging biotech leaders, VISION provides key leadership insights into the sector trends and skills required to navigate the changing bioindustry landscape.

14 November 2019:  A new Regulatory Roadshow has been designed to help SMEs and early-stage companies understand the 101 regulation when commercialising technologies. The event will help medtech SMEs further their understanding of regulatory pathways, key requirements, and when to start planning.

12 November 2019:  Updated figures demonstrating the strength of the Australian regenerative medicine (RM) sector were released at AusBiotech 2019. Over the past two years, the number of cellular therapy or RM companies in Australia has doubled. The number of research institutions involved in RM has increased from more than 30, to more than 45.

7 November 2019:  AusBiotech is seeking feedback on a recently released issues paper aimed at progressing the implementation of Gene Technology Scheme recommendations. It focuses on progressing three key priorities related to definitions, risk proportionate regulation, and streamlining regulation.

5 November 2019:  AusBiotech announced today a change in Board Directors, with CSL Limited maintaining a presence as Dr Andrea Douglas, Senior Vice President Organisation Transformation and External Affairs completes her tenure and Dr Serge Scrofani, Vice President, Strategy & Corporate Development is elected to the Board. Ms Michelle Burke was elected as Deputy Chair of the Board of Directors.

31 October 2019:  Industry Excellence Awards were announced today at the AusBiotech 2019 national conference in Melbourne. The Awards recognise innovative companies and individuals leading the way in Australia’s world-class biotechnology, medical technology and healthcare sectors.

29 October 2019:  Life science leaders and investors are assembling in Melbourne for biotech’s biggest week of 2019, with both AusBiotech 2019 and the Australia Biotech Invest & Partnering 2019 conference happening.

24 October 2019:  After a broad consultation, the TGA has issued a notice outlining how the collection, manufacture and supply of faecal microbiota transplant (FMT) products are to be regulated in Australia.

22 October 2019:  The $45 million BioMedTech Horizons (BMTH) programme is inviting expressions of interest (EOIs) from medtech innovators for funds of up to $1 million over a two-year period. The fund will support small to medium size enterprises (SMEs) in the development and commercialisation of new cutting-edge medical technologies.  

17 October 2019:  AusBiotech warmly welcomes Dr Peter French as their new Industry Development Manager, NSW - an indication of its continued support of life sciences across Australia. Dr French has strong industry connections, and will be a key part of growing the NSW life sciences industry.

 15 October 2019:  It was with sadness that AusBitoech acknowledges the passing of Dr John Holaday (1945-2019). During his time in Australia, John was an active AusBiotech member who regularly spoke at its conferences and was featured in its journal. His contribution to the global and Australian biotech scene is respected, and he will be missed.

10 October 2019:  Voting for the AusBiotech’s election ballot close on 14 October, which looks to elect a director to the one available position on the Board. Eligible members are urged to have their say and vote through the online voting emailed directly to them.

8 October 2019:  A review of the Export Market Development Grants (EMDG) scheme and Australian Government financial assistance to SME exporters has been announced by the Minister for Trade, Tourism and Investment, Senator the Hon Simon Birmingham. The review will consider how Government can make it easier and simpler for businesses to access support, consistent with the Government’s commitment to streamline service delivery.

1 October 2019:  Therapeutic Innovation Australia (TIA) has announced the opening of the latest round of its Pipeline Accelerator scheme, which will focus on support for High Throughput Screening for small molecule drug discovery.

26 September 2019:  A new report says Victoria’s pharma and medtech sector is booming, with new data released this week showing that Government support has fuelled exceptional export growth.

BiotechDispatch (26 September 2019): A new company spun-out out of the University of Melbourne has been backed by the federally-funded Biomedical Translation Fund and CSL.

BiotechDispatch (26 September 2019): Bionomics (ASX:BNO) has announced positive results from a pharmacokinetic study in healthy volunteers using the newly developed solid dose formulation of its lead drug candidate, BNC210

24 September 2019:  ANDHealth is seeking input from digital health innovators and companies to identify gaps, challenges and opportunities in digital health commercialisation. Australian Digital Health companies are invited to participate in a short, 5-10 minute survey, which closes 30 September 2019.

19 September 2019:  An Australian Biotechnology 2030 Vision (the Vision) – a decadal framework for the industry – was discussed by Minister Hunt, and supported by Minister Andrews, at the AusBiotech CEO Policy Forum in Canberra last week. Minister Hunt demonstrated his commitment to life sciences, asking AusBiotech to co-lead the development of a long-term, shared vision for biotechnology in Australia.

19 September 2019:  Online voting for the 2019 AusBiotech election ballot opened yesterday, to elect a director to the one available position on the Board.

17 September 2019:  AusBiotech is calling for expressions of interest from members to join the AusMedtech 2020 programme committee. This committee, chaired by Peter Bradley, LBT Innovations, is refreshed periodically and provides AusBiotech with guidance and expert advice on the most critical topics and issues facing the medtech sector. The committee members help shape the programme and lead the development of sessions.

12 September 2019:  Opportunities to increase business expenditure on R&D (BERD) is on the agenda at the AusBiotech CEO Policy Forum today in Canberra. It is expected that Hon. Karen Andrews MP and representatives from across relevant departments of government will join the Forum to engage on life sciences issues, with practical thought-out initiatives for increasing BERD to be presented.  

10 September 2019:  The Queensland Women in Life Sciences Luncheon brought together over 230 guests to Brisbane, bringing recent research and initiatives to the forefront in achieving a more equal gender equality standing in life sciences.

5 September 2019:  AusBiotech is considering responding to two current consultations, and is seeking member feedback into the Inquiry into supporting Australia's exports and attracting investment, and Boosting Female Founders Initiative. 

3 September 2019:  AusBiotech is commissioning research to quantify the additionality and spill-over effects of the R&D Tax Incentive (RDTI) and urgently calls on companies to help with information. With Parliament resuming next week, AusBiotech is building the evidence base to demonstrate how the proposed changes to the RDTI will disproportionally and severely effect the life sciences sector, compared to other sectors.

29 August 2019:   AusBiotech is holding a Women in Life Sciences Luncheon in Queensland next week to discuss the actions being taken within our sector to address the gender imbalance faced across the industry. Highlighted in a report released this week by the Male Champions of Change, the science, technology, engineering and maths (STEM) workforce continues to face significant challenges in attracting, advancing and retaining women.

27 August 2019:  AusBiotech has recently responded to the Senate Standing Committees on Economics’ Senate Inquiry on Intellectual Property Laws Amendment (Productivity Commission Response Part 2 and Other Measures) Bill 2019.

20 August 2019: AusBiotech is calling for early-stage projects to register for their Early Stage Investment Forum with submissions closing Friday 30 August. 

20 August 2019:  Nominations are now open for the AusBiotech Board as it seeks to elect one new director. The election outcome will be announced at the 2019 Annual General Meeting of AusBiotech Ltd, which will be held at the AusBiotech national conference at the Melbourne Convention and Exhibition Centre on Wednesday 30 October 2019 at 12.30 pm – and all members are invited to attend.

19 August 2019: Notice of AusBiotech AGM & election to the AusBiotech Ltd Board of Directors - To Members and other persons entitled to notice of Annual General Meetings of AusBiotech Ltd, an Annual General Meeting (AGM) of AusBiotech Ltd will be held at the AusBiotech national conference.

15 August 2019:  The stability of the R&D Tax Incentive (RDTI) has been identified as the most important tool for increasing business expenditure on R&D (BERD). AusBiotech is developing a policy position with practical, thought-out initiatives outlining opportunities for increasing BERD within the life sciences sector, and invites members to contribute their ideas and help inform AusBiotech’s response.

13 August 2019:  AusBiotech is calling for companies to present at Australia’s premier life science investment event: Australia Biotech and Invest Partnering 2019. This event is run for industry, by industry, and provides investment-seeking companies an opportunity to take centre-stage and make meaningful connections with the investment community. 

8 August 2019:  AusBiotech is in support of the Australian Industry Group’s (Ai Group)  R&D Tax Incentive (R&DTI) recommendations, outlined in its recently released report. Calling for stability within the innovation system, both organisations have outlined how committing to keeping this game-changing programme in its current state will improve outcomes for Australia’s economy and environment, and ultimately for Australia’s people.

6 August 2019:  AusBiotech is seeking an Industry Development Manager to continue growing the New South Wales’ (NSW) biotech sector. Expressions of interest are now open for this new part-time role for the organisation, which is an indication of its continued support of life sciences across Australia. 

1 August 2019:  Members’ ideas are being sought by AusBiotech to identify a clearly defined role that adds value, and supports, those working in the food and agritech sector. AusBiotech is uniquely placed to connect the therapeutics and agricultural/foodtech sectors, and has membership and expertise in several convergent areas - such as antimicrobial resistance, medicinal cannabis and gene editing.

30 July 2019:  The 2019 AusBiotech and Johnson & Johnson Industry Excellence Awards are now open for nominations to recognise the highest achievers in the Australian life sciences. This year’s industry awards will be presented at AusBiotech 2019 in Melbourne.

25 July 2019:  Em. Prof. Maree Smith AC will be promoting gender equality within life sciences as the keynote speaker at AusBiotech’s Queensland Women in Life Sciences Luncheon. Prominent life science leaders will share the insights that have worked and that underpin their actions to promote gender equality during the Luncheon in Brisbane on Friday 6 September 2019.

23 July 2019:  The crucial work local Australian biotech companies are undertaking to address global health concerns is being showcased in a series of case studies, launched by AusBiotech.

18 July 2019:  AusBiotech has responded to the public consultation on Australia’s Next Antimicrobial Resistance Strategy: 2020 and Beyond, stressing that industry needs to be more explicitly involved as a key stakeholder.

16 July 2019:  Global Table, the largest food business event ever staged in Australia, has released its conference programme, featuring three international keynote speakers: Secretary John F. Kerry, 68th Secretary of State, USA; Dr Howard-Yana Shapiro, Chief Agricultural Officer, Mars Incorporated, USA; and Shama Sukul Lee, Founder and CEO, Sunfed, NZ.

11 July 2019:  The Australian Competition and Consumer Commission (ACCC) has released draft guidelines on the repeal of the Intellectual Property (IP) exemption (subsection 51(3) of the Competition and Consumer Act 2010) for consultation.

9 July 2019:  Entrepreneurs and early stage businesses are invited to apply for the global competition Pitch@Palace Australia 3.0. It is a free-of-charge global opportunity working to build access and connectivity around the world.

4 July 2019 :  With the programme now launched and preparations well underway, now is the time to register for the industry event of the year; those registering before Friday 12 July will save up to $200 to attend AusBiotech 2019.

2 July 2019:  CSL are welcoming applications for their two five-year $1.25 million fellowships. The Centenary Fellowships are for early-mid career medical researchers. The fellowships are high-value awards available to Australians who wish to continue a career in medical research in Australia.

27 June 2019:  Australia has been ranked first in “attractiveness” of OECD countries for potential migrants: workers with master or doctoral degrees in the OECD’s newest policy brief on indicators of talent attractiveness.

25 June 2019:  Participants are invited to join the Australian delegation to the MedTech Conference to be held in Boston, Massachusetts from 23- 25 September 2019.

20 June 2019:  Federal Members of Parliament and Senators are being asked to engage on the threat to the Research and Development Tax Incentive (RDTI).

18 June 2019:  The $35 million BioMedTech Horizons (BMTH) programme is inviting expressions of interest (EOI), with grants of up to $1 million of funding available over a two-year period. Expressions of interest should address one of four priority therapeutic areas: cardiovascular; orthopaedics; emergency medicine/trauma; or ophthalmology.

13 June 2019:  Australia’s engagement with global pharma and medtech firms, and how health research and commercialisation can be fostered, was examined in a report released by MTPConnect during the BIO Convention in Philadelphia last week.

11 June 2019:  AusBiotech was amongst 22 country industry associations when the International Council of Biotechnology Associations (ICBA) met last week to discuss global issues impacting biotechnology development, and welcomed a new Chair, Steve Bates, CEO, UK BioIndustry Association (BIA) to succeed Andrew Casey, President & CEO, BIOTECanada.

6 June 2019:  Work is underway planning the September edition of the Australasian Biotechnology journal, and AusBiotech members are invited to submit an article abstract for consideration. The September edition will focus on therapeutics, including medicinal cannabis, the microbiome, ageing, and regenerative medicine, as well as featuring trends in the life sciences sector and a sneak peek into the AusBiotech 2019 national conference. 

4 June 2019: This year’s annual Australian delegation to the largest biotech event in the world is the most impressive participation seen to date, with all major states represented on the Australian pavilion, and over 150 companies standing united in the delegation. AusBiotech is leading the Australian contingent at the BIO International Convention 2019 in Philadelphia this week, with the Australian Pavilion as the focal point.

30 May 2019:  AusBiotech has released the annual Biotechnology Industry Survey – which this year showed that while Australia’s strength in life sciences remains in a growth trajectory, there is a worrying fall in business sentiment across the sector with uncertainty over the fate of the R&D Tax Incentive (RDTI).

28 May 2019:  Over 600 heavy hitters of medtech were involved in delivering a vibrant and successful week of activities recently to build the Australian industry. Centred around AusMedtech 2019, an engaging line-up of keynote speakers and knowledgeable panellists addressed over 350 delegates; they heard industry expertise, insight and commentary on a range of topics both practical and inspirational.

23 May 2019:  AusBiotech, with its Queensland State Committee, has provided comments on Advance Queensland’s draft strategy which aims to foster the state’s innovation system. Recognising the value of innovation, Advance Queensland developed a draft strategy Building Our Innovation Economy – Advance Queensland Strategy to guide their next phase of expanding the state’s innovation system.

21 May 2019:  The life sciences industry is united in its plea to the returned Coalition Government to consider the impacts of the proposed cuts to the Research and Development Tax Incentive (RDTI), Australia’s flagship innovation programme.

16 May 2019:  AusBiotech will be celebrating International Clinical Trials (CT) Day on 20 May, recognising the Australian leadership and excellence in CTs and the social and economic value they deliver to Australia.

14 May 2019:  Australia’s premier medtech conference, AusMedtech 2019, has grown into an eventful week with over 550 industry stakeholders, eight days of activities celebrating the medtech sector. AusBiotech is dedicated to showcasing these strengths, and the 2019 conference, and surrounding events, will once again present issues critical to industry.

9 May 2019:  AusBiotech has joined six other key industry and research groups, which are united in their pre-election call for all political parties to adopt a common approach to R&D, and to take action to support health and medical research by supporting the conditions that allow industry to do its part. 

7 May 2019:  A cohort of entrepreneurs, scientists and those working in medtech are meeting this week in Melbourne, before AusMedtech 2019, for an accelerated three-day workshop delivering medtech commercialisation skills and business acumen. The symposium will be attended by over 80 participants from across Australia, and is supported by AusBiotech as a consortium partner of the BridgeTech Programme.

2 May 2019:  The Australian medtech sector takes centre stage in the April edition of Australasian Biotechnology, AusBiotech’s official journal, in anticipation of the upcoming AusMedtech 2019 conference.

30 April 2019:  AusBiotech joined the largest Australian delegation to date at BioKorea, fostering our international connections with biotech and medtech companies and demonstrating why Australia is a global leader within the sector.

23 April 2019: Australia’s medtech conference, AusMedtech 2019, is on track to deliver a notable 50/50 split within its programme of speakers and chairs. The Australian medtech sector holds some of the world’s leading innovative companies, and AusBiotech is proud to showcase the diversity of thought leaders across them.

18 April 2019:  Businesses now have less than six months to review their IP arrangements to ensure those arrangements comply with Australia’s competition laws, after the Federal Government repealed section 51(3) of the Australian Competition and Consumer Act, in March this year.

16 April 2019:  Wearisome uncertainty continues for industry as the Research and Development Tax Initiative (RDTI) was not explicitly mentioned in the 2019 Budget announcements, but the numbers appear to assume the Bill to change the RDTI will go ahead under a Coalition government. Australia has now moved into caretaker mode with the Federal Election announced for 18 May.

11 April 2019:   The BioExchange platform is an online platform for Australian spin-outs and start-ups. It facilitates international collaboration and funding opportunities, and leverages the Asian growth market in China.

9 April 2019:  AusBiotech has responded to five medical device submissions over the past eight weeks, following a number of consultations released by the TGA. A further review is underway and in recent days, the TGA has released its Action Plan for Medical Devices. Using the insights of its members to inform its responses, AusBiotech is an active contributor to TGA proposals.

4 April 2019:  With pre-budget statements announcing a boost to medical research, the release of the 2019 Federal Budget delivered no further surprises on Tuesday night.

2 April 2019:  AusBiotech has recently engaged on the National Clinical Trials Governance Framework and the TGA’s proposal to pilot a ‘Good Clinical Practice Inspections Program’.

28 March 2019:  AusBiotech is partnering with more Australian states than ever before, to put Australia firmly front-of-mind and on the map at the BIO International Convention 2019, in Philadelphia on 3-6 June 2019.

26 Month 2019:  The Department of Industry, Innovation and Science (DIIS) is undertaking a review of existing innovation metrics to develop new metrics that better capture innovation information and support government decision-making. The Review was recommended in the Innovation and Science Australia (ISA) 2030 Plan, accepted by the Government and included as a measure within the 2018-19 Budget.

21 March 2019: AusBiotech is calling for member organisations working on active implantable medical devices (AIMD) and their accessories to comment on possible impacts of a recently released TGA proposal. The proposal includes changes relevant to some AIMD such as implantable cardiac pacemakers, implantable cardioverter-defibrillators, and cochlear implants, including associated accessories.

19 March 2019: AusBiotech is calling for session proposals for the life sciences event of the year AusBiotech 2019; to be held in Melbourne, 30 October to 1 November.

14 March 2019: This year’s Women in Life Sciences Luncheon welcomed over 320 guests in Sydney, celebrating International Women's Day, held annually on March 8 to “celebrate women's achievements throughout history and across nations”. This year’s theme More powerful together was fitting as, for the first time, AusBiotech and Medicines Australia co-hosted the day together.

12 March 2019: After much anticipation, the AusMedtech 2019 programme has been released, and with the theme ‘Bionics and beyond’, it is filled with innovative devices, ideas and discussions. AusMedtech 2019 will be held in Melbourne from 14 - 15 May 2019 at the Melbourne Convention Centre, Victoria.

7 March 2019: The AusBiotech team are delighted to officially reveal the details for their move and their new home. Staying in Melbourne, AusBiotech will be moving this weekend to 15 Queen Street, Melbourne.

5 March 2019:  Over 20 Australian companies are presenting to over 200 potential Asian investors and partners at AusBiotech’s Asian Investment Series, 26-29 March 2019.  This year, activities span the entire week and include events in Hong Kong and Shanghai, an inaugural Symposium, two bootcamps, site visits, and a trade delegation.

28 February 2019: The official communique from the third meeting of the Federal Government’s Clinical Trials Collaborative Forum centred on the coordination of the many initiatives in place to improve the landscape for clinical trials.

26 February 2019: AusBiotech is counting down the days before an incredible line up of speakers inspire delegates at the Women in Life Sciences Luncheon, in Sydney on Friday 8 March 2019.

21 February 2019: AusBiotech will be amongst the action, boosting Australia’s connections and reputation at BioKorea by supporting the Australian pavilion and conference sessions taking place.

19 February 2019:  The Australian Government has introduced the Global Talent Scheme (GTS) as a niche pilot scheme for both established companies and start-ups under the Temporary Skill Shortage (TSS) visa programme, with the aim to bring globally mobile, highly-skilled and specialised individuals to Australia.

14 February 2019: AusBiotech is about to conclude its annual consultation of membership issues, calling for leaders of biotechnology and medical technology companies to respond to the annual CEO Biotechnology Industry Position Survey 2019, to include an updated set of views. The survey closes on 22 February.

12 February 2019: The iAwards, now in their 26th year, is open and seeking to recognise Australia’s world-class digital technology innovations, individuals and organisations.

7 February 2019: AusBiotech and Medicines Australia are partnering to present this year’s annual NSW Women in Life Sciences Luncheon, to be held on International Women's Day, 8 March.

5 February 2019: The latest global industry briefing showed that 2018 was a year of significant growth in the regenerative medicine sector, with a rich and diverse pipeline producing positive data and attracting the attention of investors.

31 January 2019: The New South Wales’s Medical Devices Fund closes on Monday 25 February 2019, with over $8 million available for the 2019-2020 financial year.

29 January 2019: AusBiotech has warmly welcomed the newly-appointed AusMedtech National Advisory Group Chair, Mr Grant Bennett, and Deputy Chair, Ms Lis Boyce.

24 January 2019: AusBiotech is pleased to announce a new partnership with CSIRO, delivering 2019’s first BioCheers events in Victoria, New South Wales, and Queensland in February.

22 January 2019: AusBiotech has launched the 2019 CEO Industry Position Survey, asking leaders of biotechnology companies for their views – the good, the bad and the ugly – of our Australian life sciences sector.

17 January 2019: Following on from AusBiotech’s successful presentation of Australian life sciences at Biotech Showcase in San Francisco last week, we are already turning our attention to the next growth opportunity for our sector. AusBiotech will again lead up to 20 Australian and global life science companies to two major investment hubs in Asia.

15 January 2019: AusBiotech began the year with a bang after officially partnering with the Biotech Showcase, hosting an outstanding event at the conference, coinciding with the JP Morgan Healthcare Conference, in San Francisco last week.

20 December 2018: This year AusBiotech has seen defence of the critical RDTI, a number of gene technology relative to agriculture submissions, a change in leadership, a new strategic plan launched, and a diversity and inclusion commitment – plus new guidance and reports, an online platform unveiling, a plethora of events delivered across the country and internationally, and new Industry Excellence Award winners.

18 December 2018: AusBiotech has made a supportive submission to the TGA in response to its draft discussion paper on the future regulation of in vitro diagnostic (IVD) companion diagnostics (CDx)

13 December 2018: A new report was launched this week on ‘Digital health: Creating a new growth industry for Australia’, by ANDHealth, highlighting what is required to prosper a thriving, international digital health industry.

11 December 2018: Clinical trials are a strength for the Australian life sciences sector, however the ongoing issues of fragmentation and inefficiency within our regulatory system impacts on Australia fulfilling its true capacity and capability.

6 December 2018:  The work of MTPConnect, Australia’s medical technologies and pharmaceuticals (MTP) growth centre, is set to continue after new funding was announced by the Federal Government this week.

4 December 2018: The Senate Inquiry into the R&D Tax incentive (RDTI) Bill will now report on the 11 February 2019, after a welcome extension was granted for the Inquiry to complete its work. The Senate Committee report was initially due for release on 3 December 2018.

29 November 2018: AusBiotech announced the appointment of Dr Dean Moss as a Director - an addition that brings strong global and commercialisation experience to the AusBiotech Board  - and the departure of Lawrence Gozlan, at its Annual General Meeting.

27 November 2018: This week the International Consortium of Investigative Journalists (ICIJ) has launched The Implant Files: a global examination of the medical devices industry and its regulators.

22 November 2018: AusBiotech is inviting session proposals for AusMedtech 2019, to be held 14 – 15 May next year. This is your opportunity to have a say and lead discussions, bringing new and diverse topics to the forefront of the medtech industry.

20 November 2018: AusBiotech last week gave evidence at the Senate Inquiry on the legislative Bill that includes the R&D Tax incentive (RDTI) reforms, urging the Inquiry not to recommend its passage, until the impacts are better understood and can be mitigated.

15 November 2018: IP Australia has published a response to its consultation on draft legislation that includes measures to implement aspects of the Government’s response to the Productivity Commission’s (PC) inquiry into Australia’s IP arrangements.

13 November 2018: Three new resources have been launched recently to assist in the development of Australia’s regenerative medicine (RM) industry.

8 November 2018: AusBiotech has made a submission into a Senate Inquiry into the legislative Bill that includes the R&D Tax incentive (RDTI) reforms, urging the Inquiry to delay its passage until the impacts are better understood and can be mitigated.

6 November 2018: AusBiotech announced the appointment of Dr Dean Moss as a Director – an addition that brings strong global and commercialisation experience to the AusBiotech Board - and the departure of Lawrence Gozlan, at its Annual General Meeting.

6 November 2018: AusBiotech has extended its alliance with MTPConnect, the Growth Centre for Australia’s medical technology, biotechnology and pharmaceutical sector, by signing a new Memorandum of Understanding (MoU) to collaborate.

1 November 2018: The AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards were announced yesterday at the AusBiotech 2018 national conference in Brisbane.

30 October 2018: AusBiotech has today kicked off the biggest week of the year for biotech with the opening of its annual Biotech Invest and Partnering event in Melbourne, to be followed tomorrow by its national conference, AusBiotech 2018, in Brisbane.

25 October 2018: In support of the largest medical technology industry in Australia, the NSW Departments of Industry and Health have recently launched the NSW Medical Technology Industry Development Strategy 2018 to promote further growth and innovation in the industry.

23 October 2018: AusBiotech welcomes a Senate Inquiry for the Bill seeking to seriously reduce the R&D Tax Incentive (RDTI), after calling on the Government to delay the passage of the RDTI reform legislation until the details, mechanics and impacts are better understood and can be mitigated.

18 October 2018: AusBiotech launched its diversity and inclusion statement today, as an important first step in a wider programme of work, aimed at attracting the best and brightest talent from diverse backgrounds to biotech careers, and at fostering an inclusive industry culture.

16 October 2018: A new report released today by the Association of Australian Medical Research Institutes (AAMRI), shows that for every dollar invested in Australian medical research, we gain a $3.90 return to the economy.

11 October 2018: AusBiotech has released its 2018-21 strategic plan, with a focus on member engagement, advocacy, ensuring a sustainable organisation, strengthening its relevance and reputation, and building the sector.

9 October 2018: AusBiotech is pleased to present the Annual Report for the period 1 July 2017 – 30 June 2018, showing a year of delivery, achievement and evolution.

4 October 2018: The annual AusBiotech conference, which brings together Australian and international biotech leaders and stakeholders, will return to Brisbane this month, creating a leaders’ forum to reflect on the sector’s achievements and exchange ideas.

2 October 2018: It is anticipated that the impact of South Australia remaining GM-free will be addressed with two reviews currently underway into the South Australian (SA) GM moratorium; one by government and one by an independent reviewer.

27 September 2018: The Victorian state election, slated for 24 November 2018, has prompted 11 organisations, including AusBiotech, to make a joint statement calling on all contesting parties to adopt positions that recognise and develop the health industry as an economic priority for Victoria.

26 September 2018:  An Annual General Meeting (AGM) of AusBiotech Ltd will be held at the AusBiotech national conference at the Brisbane Convention and Exhibition Centre, Cnr Merivale and Glenelg Streets, South Brisbane, QLD 4101 on Wednesday 31 October 2018 at 12.30pm.

25 September 2018: Following a brief consultation on the R&D Tax Incentive (RDTI) reform package, the legislation has now entered the Parliament in the “strangely” titled: Treasury Laws Amendment (Making Sure Multinationals Pay Their Fair Share of Tax in Australia and Other Measures) Bill 2018

20 September 2018: Members are invited to attend the annual general meeting (AGM) of AusBiotech Ltd, which  will be held at the AusBiotech 2018 national conference at the Brisbane Convention and Exhibition Centre on Wednesday 31 October 2018 at 12.30pm.

18 September 2018: Just two weeks left to be nominated for this year’s  AusBiotech and Johnson & Johnson Industry Excellence Awards. The industry awards will be presented at AusBiotech 2018 in Brisbane, recognising the highest achievers in the Australian life sciences.

13 September 2018: Research Australia’s annual survey of views on health and medical research, Australia Speaks!, shows Australians continue to place improving hospitals and healthcare as the number one spending priority for the Australian Government.

11 September 2018: Reform to the laws on equity sourced crowdfunding are expected to be passed in the Parliament this week to include “eligible proprietary companies”.

6 September 2018: AusBiotech has submitted comment on behalf of members to two consultations: IP Australia’s consultation on the ‘Intellectual Property Laws Amendment Bill 2018; and to inform the second Australian Medical Research and Innovation Priorities 2018 – 2020 for the MRFF.

4 September 2018: A record gathering yesterday saw the opening of the AusBiotech AusAg & Foodtech Summit 2018, which is about translating Australian science into business by putting the spotlight on investment in agritech and foodtech innovation.

30 August 2018: To develop clear regulatory guidelines for the changing medical devices landscape, the CSIRO is undertaking research that will inform a TGA guidance document to assist the medical devices ecosystem to implement appropriate approaches to cyber security.

28 August 2018: The British Heart Foundation (BHF) has launched the Big Beat Challenge, a unique research funding award that will bring together world-leading researchers and innovators to identify and solve any of the biggest problems in heart and circulatory disease.

23 August 2018: With online submissions open on the Australian Medical Research and Innovation Priorities 2018–2020 until 31 August 2018, interested parties are invited to comment.

21 August 2018: The J&J Lung Cancer Innovation QuickFire Challenge will award up to $750K in non-dilutive grant funding and one year of optional residency at the new JLABS @ Shanghai for game-changing, outside-the-box solutions addressing the prevention, interception and cure for lung cancer.

16 August 2018: AusBiotech’s submission to the Food Standards Australia New Zealand (FSANZ) consultation on Food derived using new breeding techniques has formed part of a newly-released Preliminary Report summarising the submissions.

14 August 2018: In recognition of ongoing issues of fragmentation and inefficiency that impact on Australia’s attractiveness as a preferred location for clinical trials, a new Governance Framework is under development for health services undertaking clinical trials.

9 August 2018: The TGA has engaged CSIRO to conduct research to build an understanding of Australia’s innovation in ‘software as a medical device’.

7 August 2018: The latest INSEAD Global Innovation Index (2018, Energizing the World with Innovation) ranks Australia 20th overall, up from 23rd last year - showing that Australia has seen little improvement on these global measures.

2 August 2018: In the reform of the R&D Tax Incentive, AusBiotech advocated for and welcomed the recognition of the critical role that R&D expenditure plays in clinical trials (CTs) for developing life-changing and saving medicines, therapies and medical devices.

31 July 2018: The Australian agriculture sector is concerned by the European Union (EU) Court of Justice ruling that plants resulting from some of the latest plant breeding innovations, are considered genetic modification.

26 July 2018: AusBiotech is calling on the Government to delay the passage of the R&D Tax Incentive (RDTI) reform legislation until the details, mechanics and impacts are better understood.

24 July 2018: IP Australia has opened a consultation on the exposure draft of the Intellectual Property Laws Amendment (Productivity Commission Response Part 2 and Other Measures) Bill 2018 and accompanying explanatory material.

19 July 2018: Despite the welcome protection of clinical trials in the R&D Tax Incentive (RDTI) reform package, biotech start-ups will be unexpectedly hit with a 2.5 percent loss of refund.

17 July 2018: The Federal Health Minister, the Hon. Greg Hunt, has announced a new $22.3 million Biomedical Translation Bridge (BTB) grant opportunity under the Medical Research Future Fund (MRFF) to support early stage health and medical research ventures.

12 July 2018: Register before Friday 13 July to save $200 on registration to AusBiotech 2018, the industry event of the year that gathers the who’s who of Australia’s life sciences sector.

10 July 2018: The Therapeutic Goods Administration (TGA) has opened a call seeking expressions of interest from professionals in relevant scientific and medical fields to fill statutory advisory committee vacancies.

5 July 2018: AusBiotech, supported by Grant Thornton, has released the eighth annual Biotechnology Industry Survey – which this year revealed a renewed sense of optimism and strong potential for the industry to play a larger role in Australia’s economy.

3 July 2018: In the May Federal Budget, the Government announced its plan to reform the Research and Development Tax Incentive (R&DTI) and the draft legislative materials have now been published for comment.

28 June 2018: Industry is invited to take part in the Therapeutic Goods Administration’s (TGA’s) 2018 stakeholder survey, along with other stakeholders including health professionals, the medical products industry, academics and consumers.

26 June 2018: Priorities for the Medical Research Future Fund will be the topic of consultation when a national process opens on 29 June 2018 to inform the development of the next iteration of the Australian Medical Research and Innovation Priorities 2018-2020  (MRFF Priorities).

21 June 2018: The 2018 AusBiotech and Johnson & Johnson Industry Excellence Awards are now open for nominations to recognise the highest achievers in the Australian life sciences. This year’s industry awards will be presented at AusBiotech 2018 in Brisbane.

19 June 2018: Springboard Enterprises Australia’s (SBE) latest program round – Empower, Evolve, Escalate or E3 - is now open for applications. The program is designed to help develop the next generation of early-stage, female startup founders or leaders from a broad range of activities.

14 June 2018: Joining with other key industry bodies in a policy paper, AusBiotech, has recommended to the Therapeutic Goods Administration (TGA) that global harmonisation and alignment with international coding standards for the Unique Device Identification (UDI) standards are critical elements.

12 June 2018: The Queen's Birthday 2018 Honours List, released yesterday, revealed that Dr Paul Wood (FTSE) has been made an Officer of the Order of Australia (AO) for “distinguished service to science, and to global human and animal health, and through biopharmaceutical research and technological advances.”

7 June 2018: The 2018 BIO Conference in Boston is well underway, with this year marking Queensland’s 20^th mission to the conference with more than 300 Australian biotechnology representatives are attending the conference.

5 June 2018: The BridgeTech Program specialises in the commercialisation of medical technology including medical devices and diagnostics. Expressions of interest for The BridgeTech program, offering both free participation and access to a biotech product pitch competition, closes very shortly.

31 May 2018: AusBiotech has made a submission to the Department of Health in response to the Third Review of the National Gene Technology Scheme.

29 May 2018: Over 300 representatives of the Australian biotechnology sector will form a delegation to the 2018 BIO International Convention, led by AusBiotech in partnership with MTPConnect.

24 May 2018: MTP Connect, the Australian Government’s medical technology, biotechnology and pharmaceutical industry growth centre, invites participants to join the Australian delegation to The Medtech Conference to be held in Philadelphia, Pennsylvania from 23- 26 September this year.

22 May 2018: New investments have been made in recent weeks as part of the Australian Government’s $500 million Biomedical Translation Fund (BTF), including OneVentures’ investment in BiVACOR and BioScience Managers’ investment in Canary Medical Inc.

17 May 2018: A new Guide targeting potential life sciences investors for life sciences companies has been launched to build understanding of the unique life sciences sector to increase quantity and quality of investment in life sciences companies.

15 May 2018: As the ‘dust settles’ on last week’s Federal Budget and reforms to the Research and Development Tax Incentive (R&DTI), the new intensity measure is attracting attention.

10 May 2018: Support for clinical trials traverses portfolios of ‘Industry, Innovation and Science’ and ‘Health’ and their initiatives such as the Biomedical Translation Fund, the Medical Research Future Fund and strategies to make Australia a preferred destination for clinical trials.

8 May 2018: The Texas Medical Centre Accelerator (TMCx) Medical Device 2018 cohort is now open for applications until the end of this week, as it works to accelerate medical device and digital health solutions in the world's largest medical centre.

3 May 2018: Research Australia said: “Never has it been so important to highlight the crucial role health and medical research play in all our lives, so nominate those who have made a difference and ensure they get the recognition they deserve.”

1 May 2018: AusBiotech announces that Glenn Cross has decided to retire from his position as CEO but will retain his long standing relationship with the organisation.

1 May 2018: AusBiotech announces that Ms Lorraine Chiroiu (MBA, GAICD) will be appointed as its Chief Executive Officer, effective early July 2018.  This appointment follows the retirement of Mr Glenn Cross from the position, covered under separate announcement.

1 May 2018: For the third year, AusBiotech will join a sectoral gathering of organisations supporting clinical trials (on 16 May 2018) to celebrate Australian leadership and excellence in clinical trials and to mark International Clinical Trials (CT) Day.

26 April 2018: With only days until the 12th AusMedtech 2018 medical technologies conference arrives in Adelaide, attention has turned to all things medtech, including a comprehensive program and pre-event workshops on digital health, regulation and reimbursement.

24 April 2018: AusBiotech acknowledges the substantial contribution of Warren Bingham as Chair of the AusMedtech National Advisory Group as he steps down after extended service and welcomes newly-appointed Chair, Mr David Cain.

19 April 2018: On the ‘back’ of successful AusBiotech investment events in Shanghai and Hong Kong, AusBiotech is deepening its relationship and work in China with a raft of activities, including an arrangement with China BlueSky Partners to represent AusBiotech to Chinese investors.

17 April 2018: ANDHealth, an industry-led organisation focused on strengthening the Australia digital health ecosystem and de-risking innovations in digital health, is now accepting applications for the ANDHealth+ 2018 Program.

12 April 2018: AusBiotech is asking members if pre-approval of claims under the Research and Development Tax Incentive (R&DTI), might be the solution to multiple issues - enabling claimants and the Federal Government to have more certainty over the program.

9 April 2018: AusBiotech is concerned the sector will be damaged in the ‘cross-fire’ if the Treasury pushes ahead with plans to cap the Research and Development (R&D) Tax Incentive (RDTI).

5 April 2018: AusBiotech has prepared a draft response to the Food Standards Australia New Zealand (FSANZ) consultation paper, Food Derived Using New Breeding Techniques, which was released for public comment in February 2018.

3 April 2018: The Texas Medical Center Accelerator (TMCx) is looking for innovative medical device companies to take part in its upcoming Medical Device Accelerator program and is encouraging interested participants to register early.

29 March 2018: The Therapeutic Goods Administration has advised of a major update and re-structure of the Australian clinical trials handbook which provides policy guidance on the clinical trials schemes administered by the TGA.

27 March 2018: Over 450 delegates attended another hugely successful AusBiotech-hosted Asian investment series recently with fifteen Australian life science companies presenting to two major investment hubs in Asia and connecting with international investors.

22 March 2018: In a compliance update released late last week, the ASX strengthened its guidelines to stamp out the over exaggeration of gains from customer contracts and also announced immediate changes to rules relating to past misconduct by Directors.

20 March 2018: TTS Ltd and AusBiotech are pleased to announce that TTS Australia, the premier global meeting of technology transfer, is back for 2018. The two-day conference will take place on April 17 and 18 at the University of Queensland's Customs House in Brisbane.

15 March 2018: AusBiotech and Austrade will co-host the Australia National Pavilion at BioKorea 2018 and are now inviting Australian organisations to join the Australian delegation that will head to Seoul in May.

13 March 2018: The Melbourne Biomedical Precinct has taken another important step in its evolution with the launch of its new website.

8 February 2018: International Women's Day is annually held on March 8 to “celebrate women's achievements throughout history and across nations” and this year’s AusBiotech Women in Life Sciences Luncheon tomorrow in Sydney will launch the inaugural ‘Big Sisters’ program.

6 March 2018: A new Guide targeting potential life sciences investors for life sciences companies will be launched at networking events in Sydney and Melbourne – and registration is now open.

1 March 2018: AusBiotech has emphasised the views of industry in two submissions:  Updating GT Regulation (Australia) & draft amendments to GT Regulations; a joint response Inquiry into compensation mechanisms for economic loss to WA farmers caused by GM material contamination.

27 February 2018: AusBiotech is about to conclude its annual consultation of membership issues, calling for leaders of biotechnology and medical technology companies to respond to the annual CEO Biotechnology Industry Position Survey 2018, to include an updated set of views.

22 February 2018: This year’s AusBiotech Women in Life Sciences Luncheons in Sydney and Brisbane focus on the power of ‘sisterhood’ with the theme, ‘Sisters in Life Sciences’ and the call is about to close for Big Sisters.

20 February 2018: The Medical Countermeasures Program is developing and delivering product solutions and strategies to benefit civilian and military health in Australia and globally. The Program invites health and medical researchers and industry colleagues from the diagnostics, medtech and pharmaceutical sectors.

15 February 2018: The Australia-China Agricultural Cooperation Agreement (ACACA) 2018 grant opportunity is now open for applications to develop Australia's agricultural trading relationship with China.

13 February 2018: A key plenary session at AusMedtech 2018 will present the inventor of world-first low cost dialysis system, as the medical devices and diagnostics sector gather in May for the eleventh annual industry conference.

8 February 2018: This year’s AusBiotech Women in Life Sciences Luncheons in Sydney (9 March) and Brisbane (16 March) focus on the power of ‘sisterhood’ with the theme, ‘Sisters in Life Sciences’ and how this bond amongst women can further galvanise diversity in life sciences.

6 February 2018: Initial feedback from the life sciences sector finds the Innovation and Science Australia (ISA), 2030 strategic plan is another example of a plan skewed away from the needs of life sciences to short-horizon innovation.

1 February 2018: AusBiotech has launched its annual consultation of membership issues, calling for leaders of biotechnology companies to respond to the annual CEO Biotechnology Industry Position Survey 2018, as a matter of importance.

30 January 2018: Austrade's newly released Clinical Trials Industry Capability Report features Australia’s competitive advantage as a world-leading location for clinical research of new therapeutic products and medical devices.

25 January 2018: Expected to improve dramatically time-to-market, a new priority designation process for eligible medical devices has opened with guidance documents from the Australian Therapeutic Goods Administration (TGA).

23 January 2018: AusBiotech is calling for session proposals for the life sciences event of the year, AusBiotech 2018 to be held in Brisbane 31 October to 2 November. Help shape the program and submit a session proposal, which will be considered by the program committee, until 31 January 2018.

18 January 2018: Submission preparation continued over the December/January break with AusBiotech lodging one submission in late December and two lodged so far in the New Year, including a response to the Senate Inquiry into the TGA ‘Measures’ Bill.

16 January 2018:  Last year ended on a high with a buoyant sector, confidence at an all-time high and funds flowing into the sector from the Medical Research Future Fund and its $500 million Biomedical Translation Fund (BTF), as well as MTP Connect grants underpinning a flurry of quality activity.

22 December 2017: The AusBiotech office will be closed over the holiday period from 12:00 noon Friday 22 December 2017 until 9.00am Wednesday 3 January 2018.

21 December 2017: A buoyant sector, confidence at an all-time high & funds flowing into the sector from the Medical Research Future Fund & its $500 million Biomedical Translation Fund (BTF), as well as MTP Connect grants, have helped shape a successful year for the Australian biotechnology industry & AusBiotech.

19 December 2017: The Senate has referred the most recent TGA Amendment Bills for Inquiry, delaying the implementation of a raft of recommendations of the Medicines and Medical Devices Regulation Review (MMDR).

14 December 2017: The Premier of Victoria and the Australian Society for Medical Research (ASMR) have called for nominations for the 24th Premier's Awards, which has five categories across health and medal research.

12 December 2017: AusBiotech has announced the appointment of a Director – Dr Megan Baldwin, CEO and Managing Director of Opthea Limited – which strengthens the AusBiotech Board with expertise in life sciences industry leadership.

7 December 2017: Expressions of interest are open to join Australia’s delegation to the BIO International Convention 2018, to be led by AusBiotech and also to join MTPConnect’s CEO, Sue MacLeman, and Office of Innovation and Science Australia CEO Dr Charlie Day on a mission to Israel in May 2018.

5 December 2017: In addition to appointing Australia’s first intellectual property (IP) Counsellor to China, IP Australia’s have developed new guides to assist Australian business navigate the Chinese IP system.

30 November 2017: The TGA is seeking comments on future options for the regulation of personalised and 3D printed medical devices to contribute to the development of a regulatory framework.

28 November 2017: AusBiotech is currently seeking expressions of interest (EOI) in joining the Intellectual Property (IP) Expert Panel, to increase its size and also to broaden its purview to encompass medicines.

23 November 2017: AusBiotech, informed by its IP Advisory Panel, has made submissions on the IP Australia consultations on amending the inventive step for patent claims and introducing an objects clause.

21 November 2017: The National Training Package for the pharmaceutical industry is going through a once-a-decade review and board industry input is invited to improve the outcomes and relevance for the sector.

16 November 2017: With more than 15 cellular therapy companies focussed on product development and infrastructure support, Australia is demonstrating an emerging strength with an active regenerative medicine eco-system with internationally-recognised basic and translational research.

14 November 2017: Members are invited to comment this week on responses to two consultations underway with IP Australia, regarding changes to the inventive step for patent claims and the introduction of an objects clause.

9 November 2017: The Therapeutic Good Administration (TGA) has released draft guidance documentation for the Provisional Approval pathway for prescription medicines that is currently being developed in response to recommendations of the Medicines and Medical Devices Regulation Review.

7 November 2017:  While the Review of the National Gene Technology Scheme is underway in stages, industry has welcomed the interim outcome of the 2016 Technical Review of the Gene Technology Regulations, and signals commencement of phase two of the 2017 consultation.

2 November 2017: AusBiotech committees and advisory group Chairs took advantage of the national gathering at AusBiotech 2017 last week to meet and update one another on the work of respective groups.

1 November 2017: A new sector ‘snapshot’ has revealed  the magnitude of the life sciences sector for the first time, confirming that there are approximately 232,218 people employed in the Australian life sciences sector, across 1,653 organisations.

31 October 2017: The AusBiotech 2017 annual national meeting held last week in Adelaide has demonstrated the buoyancy of the sector after attracting 985 delegates from 18 countries to network, collaborate and discuss sector successes and issues.

26 October 2017: AusBiotech announced the election of Professor Jan Tennent as a Director at today’s Annual General Meeting – an addition that will bring a strong industry-research conduit to the AusBiotech Board.

24 October 2017: Australia's biggest yet biotech investment event, Australia Biotech Invest 2017, has opened today in Melbourne, attracting 29 presenting companies and 310 delegates.

19 October 2017: AusBiotech strengthened its international partnerships in regenerative medicine, with a memorandum of understanding (MoU) signed with the peak Japanese industry body.

17 October 2017: The Federal Government has progressed its Prostheses List reform agenda by striking a four-year agreement with the medical devices industry, with the intent of delivering certainty and stability for the industry while restricting private health insurance (PHI) premium increases for consumers.

12 October 2017: An Annual General Meeting (AGM) of AusBiotech Ltd will be held at the AusBiotech national conference at the Adelaide Convention Centre, North Terrace, Adelaide, SA 5000 on Wednesday 25 October 2017 at 12.30pm.

12 October 2017: In further work on skilled migration visa provisions, the Federal Government has made the Department of Employment (DoE) responsible for reviewing and recommending eligible occupations and revealed the process for the next update of lists on 1 January 2018.

10 October 2017: AusBiotech and its AusMedtech Regulatory Affairs Expert Panel have made a submission to the TGA in full support of the recommendation to up-classify surgical mesh products to align with the revised European regulations.

5 October 2017: A new Uniform Recall Procedure for Therapeutic Goods 2017 (URPTG) (V2.0, October 2017) has been released for a “familiarisation period”, with the revision due to come into effect on Monday 15 January 2018.

2 October 2017: The AusBiotech 2017 Annual Report, launched yesterday, shows an organisation committed to the industry and positive growth indicators for the sector.

2 October 2017: Members have received a Notice dated 14 August 2017 for the Annual General Meeting (AGM) of AusBiotech Ltd to be held at the AusBiotech national conference at the Adelaide Convention Centre, North Terrace, Adelaide, SA, 5000 on Wednesday 25 October 2017 at 12.30pm.

28 September 2017: IP Australia has opened five simultaneous public consultations on IP policy matters, four of which relate to IP Australia’s proposed implementation of the Government’s response to the Productivity Commission’s 2016 report on Australia’s IP arrangements.

26 September 2017: For a limited time, AusBiotech will host a China Market Desk, manned by Austrade Shanghai’s Senior Business Development Manager (BDM), Mr Andre Zhu.

21 September 2017: ANDHealth, Australia’s first industry-led national accelerator for digital health technologies, has announced the six companies that will participate in its first cohort to benefit from a hands-on advisory group, drawn from a field of 55 applicants.

19 September 2017: Online voting for the 2017 AusBiotech election ballot opened yesterday, to elect a director to the one available position on the Board. Long-standing and high profile members are among the candidates for this year’s election.

14 September 2017: Renowned cancer researcher and Nobel Laureate, Dr Harold Varmus, will present the 2017 Graeme Clark Oration on Monday 30 October in Melbourne.

7 September 2017: AusBiotech is pleased to invite you to the Melbourne or Sydney launch events of the recently-completed Roadmap to a successful IPO for life sciences companies.

5 September 2017: Nominations for the AusBiotech Board close 11 September for the election of one new director. AusBiotech will notify the membership of the final candidates shortly after nomination close. Voting will open on 18 September 2017.

31 August 2017: The Agricultural Biotechnology Council of Australia (ABCA) launched the third edition of The Official Australian Reference Guide to Agricultural Biotechnology and GM Crops at the AusBiotech AusAg & Foodtech Summit in Adelaide this week.

29 August 2017: The AusBiotech AusAg& Foodtech Summit 2017 has commenced today in Adelaide, putting the spotlight on investment in agritech and foodtech innovation to help bridge Australian science and business.

24 August 2017: Following the welcome restoration of a number of sector-related occupations on the list for skilled migration visas announced in June (effective 1 July), the Government has opened a public consultation on reforming Australia’s visa system and designing a new and more simple system.

22 August 2017: This year’s industry Awards will recognise the highest achievers in the Australian life sciences with the AusBiotech and Johnson & Johnson Industry Excellence Awards now open. The awards will be presented at AusBiotech 2017 in Adelaide.

17 August 2017: The award-winning Industry Mentoring Network in STEM (IMNIS) MedTech-Pharma Program has now been launched across Australia, after the program was funded on the back of a successful pilot.

15 August 2017: Nominations are now open for the AusBiotech Board as it seeks to elect one new director. The election outcome will be announced at the 2017 Annual General Meeting of AusBiotech Ltd to be held at the AusBiotech national conference at the Adelaide Convention Centre.

14 August 2017: Notice of AusBiotech AGM & election to the AusBiotech Ltd Board of Directors - To Members and other persons entitled to notice of Annual General Meetings of AusBiotech Ltd, an Annual General Meeting (AGM) of AusBiotech Ltd will be held at the AusBiotech national conference.

10 August 2017: AusBiotech will work on the 2017 Graeme Clark Oration with the Convergence Science Network and the University of Melbourne to present Australia’s most prestigious free public science event on Monday 30 October at the Melbourne Convention and Exhibition Centre.

8 August 2017: Australian medical device and biotech companies developing prosthetic technologies and products are called upon to share their progress after the Federal Department of Health requested a quarterly briefing document, through the Prostheses List Advisory Committee (PLAC).

3 August 2017: AusBiotech’s Australian Life Science Innovation Directory, launched just over a year ago, is
attracting significant attention and members are reminded to check and update details ahead of the largest Australian life sciences event, AusBiotech 2017 in October.

3 August 2017: AusBiotech are pleased to support the TGA Medical Devices Sponsor Information Day. This event is focused on new regulatory staff.

1 August 2017: OneVentures and leading US venture capitalist Jim Scopa are gearing up for an Australian roadshow to look for investment opportunities – and local companies are invited to express interest in meeting.

27 July 2017: MTPConnect will lead a delegation to attend The MedTech Conference (formerly AdvaMed) September 25 – 27, 2017 San Jose, California, to showcase Australia’s outstanding innovative medtech companies and build invaluable inroads into international markets.

25 July 2017: Biotech Capital Limited (ASX: BTC) announced yesterday it will commence trading as BTC Health, remaining a listed company on the ASX and registered as a Pooled Development Fund.

20 July 2017: A number of AusBiotech committees are seeking new members and AusBiotech is calling for expressions of interest to join selected committees. AusBiotech’s work in the life sciences industry is informed by and driven by a strong network of state-based and program committees.

18 July 2017: Amid a range of changes to visa provisions, the Federal Government has commenced a review of Australia’s business, investment and talent visas, including Significant and Premium Investor Visa (SIV and PIV).

13 July 2017: The Victorian Clinical Trials Gateway (VCT Gateway) – a new web-based portal - has been launched to globally connect the clinical trials ecosystem with and in Victoria.

11 July 2017: Innovative South Australian companies are set to receive an additional $50 million in external venture capital with the announcement of the State Government’s 15 year, South Australian Venture Capital Fund (SAVCF) – to be managed by Blue Sky Venture Capital.

6 July 2017: Johnson & Johnson have launched a new global scholarship program to support mid-career women continue their academic journey called the Women in STEM²D program. Australian, women who are PhDs working in STEM are encouraged to apply.

4 July 2017: Mid-stage evidence-based digital health technologies, which have achieved proof-of-principle, are encouraged to apply for the ANDHealth+ 2017 Program, which opened last week to support projects to progress technology towards investment.

29 June 2017: Agritech and foodtech companies are invited to express interest in pitching to investors and showcase their company’s potential at the up-coming AusAg & Foodtech Summit 2017.

27 June 2017: Australian life sciences companies are encouraged to apply for The Governor of Victoria Export Awards (GOVEA), which rewards Victoria’s most successful and innovative exporters with business recognition in local and international markets.

22 June 2017: The Therapeutic Goods Administration (TGA) is working to implement an electronic application form for prescription medicines and a notification process for very low-risk changes to registered medicines, and is seeking feedback from industry stakeholders.

20 June 2017: The international BIO conference in San Diego has commenced with the AusBiotech-led delegation comprising more than 250 Australians and Queensland Premier Annastacia Palaszczuk announcing support for AusBiotech 2018, Australia’s national life sciences conference, to return to Brisbane.

16 June 2017: Sienna Cancer Diagnostics (ASX:SDX) CEO, Matthew Hoskin, discusses its diagnostic technology and upcoming IPO with Finance News Network

15 June 2017: A new report compiled by Australia’s peak body for venture capital (VC) and private equity (AVCAL) – ‘The Venture Capital Effect’ – reveals Australia’s VC sector has soared ahead in recent years with a record $568 million raised in 2016.

13 June 2017: Greater support for navigating Australia’s therapeutic goods regulation is now available for SMEs with SME Assist, a new TGA service, launched on Friday by the Minister for Health, the Hon. Greg Hunt MP.

8 June 2017: AusBiotech is seeking immediate feedback from members outlining how the 457 visas abolition and its replacement with a new Temporary Skill Shortage (TSS) visa will impact life sciences organisations, in an effort to repair the skilled occupations list.

6 June 2017: AusBiotech is inviting SMEs, startups and innovators with commercial-ready technologies to showcase the potential of their companies at the AusAg & Foodtech Summit 2017.

1 June 2017: DibbsBarker, with support from AusBiotech, has launched IP Ready, a free online assessment tool designed to help life science companies understand the main forms of IP and identify gaps in their own IP knowledge.

This year’s industry Awards will recognise the highest achievers in the Australian life sciences with the AusBiotech and Johnson & Johnson Industry Excellence Awards now open. The awards will be presented at AusBiotech 2017 in Adelaide.

Australia’s world-class clinical trial capabilities are set to grow, with a $33 million funding boost announced by Health Minister the Hon. Greg Hunt MP on International Clinical Trials Day.

With digital health industry forming and growing quickly across the traditional life sciences space, investment in the area is shaping up actively with a record number of companies funded with ‘seed’ and ‘series A’ investments.

Startups are invited to apply for the “Sunan Cup” Startup Competition (Australian Division), representing a valuable opportunity for early-stage companies to engage with China.

The Senate Inquiry report on ‘Price regulation associated with the Prostheses List Framework, which was presented to the Senate last week, agreed with recommendations that the pricing reform process ought not disadvantage Australian manufacturers.

The Australian Safeguards and Non-Proliferation Office (ASNO), on behalf of the Australian Government, is inviting chemical production companies to participate in the Survey on Production of Discrete Organic Chemicals via bioremediated processes.

A decision regarding the R&D Tax Incentive looms tonight, as the Australian biotech industry awaits  the Government’s response to the ‘Ferris, Finkel, Fraser’ Review of the R&D Tax Incentive, which is expected to be included in the 2017-18 Federal Budget.

The Therapeutic Goods Administration (TGA) is seeking feedback on the future regulation of ‘low risk’ products in Australia, which encompasses products that pose little or no risk to the health of consumers.

AusBiotech’s annual survey of biotechnology industry CEOs shows the strongest year on record, but the result is overshadowed by pervasive fear that proposed changes to the Research and Development (R&D) Tax Incentive will damage Australia’s flourishing and globally-competitive sector.

Australian exporting companies are invited to participate in Australia’s International Business Survey (AIBS), which seeks to understand characteristics of Australian exporters and how to assist their international activities.

The Australian medtech sector takes centre stage in the April edition of Australasian Biotechnology, AusBiotech’s official journal, in anticipation of the upcoming AusMedtech 2017 and International Conference on Mechanics in Medicine and Biology (ICMMB) 2017 conference.

AusBiotech has joined fellow organisations - Research Australia, Medicines Australia, Medical Technologies Association of Australia and BioMelbourne Network – in a joint statement urging the Federal Government not to devastate Australia’s most innovative industry by gutting the Research & Development (R&D) Tax Incentive.

The AusBiotech-led Asian Investment Series has confirmed investor interest in the Australian life science industry is strong and intensifying.

Leading provider of peptides for cancer research, Mimotopes, is facing eviction from its $10 million purpose-built facility and ultimately ceasing operations altogether, after notice to exercise its lease renewal was late due to a clerical oversight.

Preserving the R&D Tax Incentive will be top priority as AusBiotech coordinates comment for Innovation and Science Australia’s (ISA) consultation to develop a 2030 Strategic Plan for Australian innovation, science and its research system.

AusBiotech has made a submission endorsing proposed changes to improved access options for unapproved therapeutic goods, which are intended to reduce time and administrative burden and greatly improve efficiencies for applicants.

Australian technology accelerator program, Australian Technologies Competition, is now open for 2017 to Australian technology SMEs with global potential.

The second AusBiotech NSW Women in Life Sciences Luncheon was warmly received as guest speakers, Melissa McGregor, Dr Elizabeth Eastland and Jacqueline Savage, united and inspired the 270 women who attended.

The Australian life sciences industry is invited to assist in the 2017 National Capability Audit for the Medical Countermeasures (MCM) Initiative. 

The TGA is investigating ways that it might provide support for small and medium enterprises (SMEs) in accessing regulatory guidance, and seeks feedback on the key themes that emerged in initial discussions with AusBiotech and industry.

Industry advocacy at AusBiotech is in ‘top gear’ with nine submissions completed on behalf of members in the past 12 weeks and two due by the end of the month.

AusBiotech is set to give evidence at this week’s Senate Inquiry into the reform of prostheses pricing, which has proven to be a complex and confusing debate on how to best address the system of pricing products on the Prostheses List for implantable medical devices used in private hospitals.

AusBiotech had made a submission to the Senate Inquiry on the Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016, urging that the Bill be supported to enable regulatory reform measures stemming from the review of Medicines and Medical Devices Regulation (MMDR).

AusBiotech has welcomed the Victorian Medical Research Acceleration Fund, a new grant fund aiming to accelerate early-stage commercialisation of health and medical research and support its translation into health and economic outcomes.

Industry CEOs are invited to contribute to AusBiotech’s annual consultation on membership issues for biotechnology companies, which closes for 2017 on 17 March 2017.

The newly-appointed Minister for Industry, Innovation and Science, Senator Arthur Sinodinos, has announced an intention to establish a women’s advisory to guide policy in the innovation sector.

Constant reviews and recent changes to the Research and Development (R&D) Tax Incentive are jeopardising Australian innovation and prompting Australian biotechnology firms to reconsider their R&D investment strategy, says the McKell Institute.

AusBiotech has responded to Food Standards Australia New Zealand (FSANZ) call for comment on the draft Cost Recovery Implementation Statement (dCRIS).

Emerging life science companies are encouraged to take advantage of Asia’s propitious investment landscape and join AusBiotech’s Asian Investment Series.

The passage of a legislative bill to enable regulatory reform measures stemming from the review of Medicines and Medical Devices Regulation (MMDR) was last week delayed with its referral for Inquiry.

The International Conference on Mechanics in Medicine and Biology (ICMMB) scientific program committee has made its final call for abstracts.

AusBiotech is inviting members to express interest in joining a new advisory group to provide guidance and advice on policy impacting clinical trials (CTs).

AusBiotech has launched its annual consultation of membership issues, calling for leaders of biotechnology companies to respond to the annual CEO Biotechnology Industry Position Survey 2017, as a matter of importance.

AusBiotech has made a submission to the Senate’s Community Affairs References Committee Inquiry into the ‘Price regulation associated with the Prostheses List Framework’, urging the Inquiry to carefully consider the impacts of pricing reforms.

AusBiotech has recently been the subject of misrepresentation in attempts to defraud people. Read about phishing emails and tips to detect them.

Australia is positioned well in biotechnology to deliver on its promise for the future as a driver for the Australian economy.

The Federal Government has invited stakeholder views after releasing the final report on the Productivity Commission’s (PC) inquiry into Australia's intellectual property arrangements.

AusBiotech, supported by the AusMedtech Regulatory Affairs Expert Panel, has submitted to two medical device consultations that form part of the Medicines and Medical Devices Review (MMDR).

Digital health start-ups with monitoring and data collection technologies that might address Australia’s alarming rate of stillbirth are invited to apply for a supported accelerator program.

As the pace picks up after the festive break and the realities of our respective New Year’s resolutions settle on us, AusBiotech starts the year with a renewed focus on leadership in policy and a resolution to continue committed advocacy for innovation in life sciences.

The International BioFest 2016, AusBiotech’s 30th anniversary and our sector’s ranking among the global top five helped shape a momentous and action-packed year for the Australian biotechnology industry.

AusBiotech has made a submission to the Technical Review of the Gene Technology Regulations 2001, ‘Discussion paper: Options for regulating new technologies’.

Loss of life science jobs, access to direct investment, clinical trial losses and risk to Australia’s global competitiveness were shown to be significant issues in AusBiotech’s recent survey of Australian life science companies.

Dr Greg Roger has been appointed to the reconstituted Prostheses List Advisory Committee (PLAC) that will develop, consult and advise the Government on further changes to the prostheses listing arrangements.

The 14th Annual Biopharmaceutical Manufacturing Report and Survey, BioPlan Associates’ global benchmarking and analysis study, is now open.

The TGA has invited comment on the proposed accelerated pathways for medical devices and Australian conformity assessment bodies for medical devices, as part of further consultations on elements of the Medicines and Medical Devices Review (MMDR).

The proposed $2 million cap on the R&D Tax Incentive will seriously damage clinical trials activity in Australia, should the Federal Government proceed with the measure.

As the TGA implements detailed consultation on elements of the Medicines and Medical Devices Review (MMDR), comment is now sought on proposed criteria to identify comparable overseas regulators (CORs) for prescription medicines. 

AusBiotech says it does not support the proposed changes as a package, as it is a firm belief that this effort to limit or divert the R&D Tax Incentive will damage our hard-won momentum in life sciences.

A consultation on the ‘Ferris, Finkel, Fraser’ Review of the Research & Development (R&D) Tax Incentive and its recommendations will receive a strong message objecting to the recommendation of a $2 million cap on the refundable component of the programme that would disadvantage a significant portion of SMEs in the sector. 

AusBiotech has provided a submission in response to the Productivity Commission’s Intellectual Property (IP) Arrangements Draft Report, disagreeing with numerous recommendations in regard to patents and data protection.

This week's Federal Budget revealed a welcome response to the Review of Medicines and Medical Devices Regulation, that will provide industry with savings of around $75 million per annum, by reducing red tape and regulation on the pharmaceutical and medical device industries.

The Australian Intellectual Property Report 2016 provides a detailed breakdown of the nation's intellectual property (IP) trends.

AusBiotech and the Australian Innovation and Manufacturing (AIM) Incentive Group have made a joint submission to the Joint Select Committee on Trade and Investment Growth’s inquiry into Australia’s Future in Research and Innovation.

AusBiotech has continued publishing ‘30 success stories in 30 days’ on its website, showcasing the impressive achievements of Australia’s biotechnology industry. Read installments 4 – 9 of the stories about companies, people and products that have contributed to the success of the sector. 

Bill Ferris briefs on Biomedical Translation Fund February 9, 2016 Latest News, Policy The Chair of recently established Innovation and Science Australia, Bill Ferris AC, spent Monday briefing the biotechnology sector on the $500 million Biomedical Translation Fund (BTF).

AusBiotech had begun publishing ‘30 success stories in 30 days’ on its website, and you are invited to add your story. Read the first installments of the stories about companies, people and products that have contributed to the success of the sector. 

Registrations have opened for the much-anticipated International BioFest 2016 that will combine three major events in one week in Melbourne (24 – 27 October 2016), making it the largest life sciences gathering ever seen in Australia.

In what has been dubbed by Australia’s Prime Minister as the “year of innovation”, AusBiotech calls on leaders of biotechnology companies (CEOs and MDs) to respond to the annual CEO Biotechnology Industry Position Survey 2016 as matter of importance.

AusBiotech is pleased to announce its inaugural ‘Women in Life Sciences’ luncheon will be held in NSW, the week that commences with International Women’s Day, Friday 11 March 2016.

AusBiotech will publish 30 biotech success stories on its website, one a day, starting from 1 February and reaching a crescendo on 1 March 2016 with the launch of the 30th anniversary historic edition of the journal, Australasian Biotechnology.

This year will see a range of activities to celebrate the occasion, including a special historic edition of the journal, Australasian Biotechnology in 1 March and a gala luncheon event mid-year, building to the crescendo with the International BioFest 2016 in October - the largest ever gathering of life sciences in Australia.

Tax breaks for investors in early stage innovative companies and a new Biomedical Translation Fund to support commercialisation were among the long-advocated-for highlights delivered today as AusBiotech welcomed the Turnbull Government’s launch of its National Innovation and Sciences Agenda (NISA).

A report to the Australian Government, Patent Box Policies, has provided a limited and unhelpful assessment of patent box policies. The report admits a "lack of economic models and empirical evidence prevent quantitative estimates". 

AusBiotech has provided an online response to the Medicines and Medical Devices (MMD) First Report Stakeholder forum, which discussed the review of medicines and medical devices regulation.

AusBiotech, last week, represented the industry at invitation-only forums, held by the Deregulation Branch of the Federal Department of Health to discuss the first report on the review of medicines and medical devices regulation, which was released on 31 March 2015.

The Federal Minister for Small Business, the Hon Bruce Billson, has released a consultation paper on extending crowd-sourced equity funding (CSEF) to small proprietary companies.

On the back of last year's savage Budget cuts to industry support and science programs, the biotech industry can be relieved it was not again targeted for direct savings. However, nor does this year’s Federal Budget offer excitement for the industry in terms of innovation stimulus.

A forum was held last week as the first step in the recently-announced independent review of medicines and medical devices regulation.

Further to the recent launch of the Industry Innovation and Competitiveness Agenda, the Federal Government has announced the establishment of an independent panel to undertake a review of medicines and medical devices regulation in Australia.